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Summary 
The transcription factor AP-1 is built up by dimerization of Jun and Fos family members 
and regulates major biological events like proliferation, invasion and apoptosis. The dimeriza-
tion pattern of AP-1 changes when HPV-positive cells undergo malignant progression. While 
in HPV-positive non-malignant cells (“444”) AP-1 is composed of c-Jun/Fra-1, their malignant 
counterparts (“CGL3”) mainly express c-Jun/c-Fos heterodimers. Since microRNAs (miRNA), 
a potent group of post-transcriptional regulators, are often deregulated during malignant trans-
formation, the regulation of AP-1 by miRNAs during cancer progression was analyzed. 
For this purpose, Drosha and Dicer, the key processing proteins in miRNA biogenesis, 
were knocked down by siRNAs. Quantitative RT-PCRs and Western blots showed that Fra-1 
was regulated by miRNAs in non-tumorigenic and tumorigenic hybrids, but not in parental tu-
morigenic HeLa cells. c-Jun is repressed by miRNAs only in 444 and HeLa cells, but not in 
CGL3 cells, which express only low amounts of c-Jun. Conversely, c-Fos is indirectly up-
regulated by miRNAs in HeLa cells. As analyzed by electro-mobility-shift / super shift-assays, 
the observed changes in protein expressions also resulted into modulations of AP-1 dimer 
composition that were also confirmed by AP-1 responsive Luciferase assays (TRE-Luc). Fur-
thermore, reporter constructs harboring the 3’UTRs of c-Jun and Fra-1 showed direct regula-
tion by miRNAs throughout the full-length 3’UTRs suggesting multiple miRNA binding sites 
and / or multiple regulatory miRNAs. Using an “Illumina” miRNA expression array, differentially 
expressed miRNAs in the non-tumorigenic and tumorigenic cell hybrids were detected and 
matched with miRNAs that were predicted to regulate c-Jun according to a bioinformatics 
analysis with PicTar, TargetScan, miRBase and DIANA microT. The data pointed towards 
miR-495 as one regulatory miRNA targeting c-Jun. Preliminary luciferase assays with over-
expressed miR-495 did not reveal an interaction with a reporter construct harboring c-Jun 
3’UTR. Other potential candidates were not tested. 
These results show for the first time that c-Jun and Fra-1 are direct targets of miRNAs 
and that c-Fos is submitted to an indirect miRNA regulation, thereby expanding known 
miRNA-c-Fos regulatory circuits. Moreover, it is demonstrated that miRNAs can modulate AP-
1 composition and transcriptional activity in cervical carcinoma cells with potential conse-
quences on AP-1 target genes. 
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Zusammenfassung 
Der Transkriptionsfaktorkomplex AP-1 entsteht durch Dimerisierung von Jun und Fos 
Proteinen und reguliert wichtige biologische Prozesse wie Proliferation, Invasion und Apopto-
se. Die AP-1 Zusammensetzung ändert sich während der malignen Transformation HPV-
positiver Zellen. Während die AP-1 Dimere in HPV-positiven, nicht malignen Zellhybriden 
(„444“) vor allem aus c-Jun/Fra-1 bestehen, exprimieren maligne Zellhybride („CGL3“) c-
Jun/c-Fos Heterodimere. Da microRNAs (miRNA) eine bedeutende Rolle bei der post-
transkriptionellen Regulation spielen und durch maligne Transformation oft dereguliert sind, 
wurde die Regulation von AP-1 durch miRNAs vor dem Hintergrund der Krebsentwicklung un-
tersucht. 
Für diesen Zweck wurden Drosha und Dicer, Schlüsselenzyme in der miRNA Bioge-
nese, durch siRNAs supprimiert. Die anschließende Analyse mittels quantitativer RT-PCR und 
Western blots zeigte, dass Fra-1 in den nicht-tumorigenen und tumorigenen Zellhybriden re-
guliert ist, nicht aber in den parentalen, tumorigenen HeLa Zellen. c-Jun wird in 444 und HeLa 
Zellen durch miRNAs kontrolliert, während in CGL3 Zellen, die nur geringe Mengen c-Jun 
exprimieren, eine solche Regulation nicht gefunden wurde. Im Gegensatz dazu wurde ge-
zeigt, dass c-Fos nur in HeLa Zellen indirekt durch miRNAs reguliert ist. Die Suppression der 
miRNAs führte zu stöchiometrischen Veränderungen von AP-1, was mittels „electro-mobility-
shift/super shift-assays“ (EMSA) gezeigt werden konnte. Darüber hinaus wurde auch die 
transkriptionelle Aktivität von AP-1 moduliert, wie am Beispiel von AP-1 sensitiven Luciferase 
Experimenten (TRE-Luc) verdeutlicht wurde. Weiterhin zeigten Luciferase Experimente mit 
Reporterkonstrukten der 3’UTRs, dass c-Jun und Fra-1 direkt durch mehrere miRNA Binde-
stellen und / oder mehrere miRNAs inhibiert werden. Um die verantwortlichen miRNAs zu 
identifizieren, wurde ein miRNA Expressionsprofil der nicht-tumorigenen und tumorigenen 
Zellhybride erstellt. Der Abgleich unterschiedlich exprimierter miRNAs mit miRNAs, für die ei-
ne regulatorische Funktion durch in-silico Analysen (PicTar, TargetScan, miRBase and DIANA 
microT) vermutet wird, deutete auf miR-495 als verantwortliche miRNA für c-Jun hin. Jedoch 
zeigten vorläufige Luciferase Experimenten mit überexprimierter miR-495 keine Interaktion mit 
den c-Jun Reporterkonstrukten. Andere potentielle miRNAs wurden nicht getestet. 
Diese Ergebnisse zeigen zum ersten Mal, dass c-Jun und Fra-1 direkt durch miRNAs 
reguliert werden, und dass c-Fos einer indirekten miRNA Regulation unterliegt, was die bishe-
rigen Kenntnisse über die miRNA-c-Fos Regulation erweitert. Des Weiteren zeigt diese Arbeit, 
dass miRNAs die Zusammensetzung und die transkriptionelle Aktivität von AP-1 in Gebärmut-
terhalskrebs Zelllinien mit möglichen Auswirkungen auf AP-1 Zielgene modulieren können. 
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1. Introduction 
1.1. Cervical cancer and human papillomaviruses 
Cervical cancer is one of the most common cancers in women worldwide, with an es-
timated global incidence of 470,000 new cases and approximately 233,000 deaths per year 
(Parkin et al., 2001; Bosch and de Sanjose, 2003). Among all cancer types, cervical cancer is 
the primary cause of death of women in many developing countries, where widespread 
screening by cervical cytology is still unavailable (Cronje, 2004). In developed countries, the 
incidence is lower as a consequence of cervical screening and ongoing active health educa-
tion programs (Pecorelli et al., 2003). In future, the incidence will hopefully further decrease 
due to large-scale vaccination programs started in 2007. 
The development of cervical cancer is a multi-stage process lasting, from several 
years up to decades (zur Hausen, 1996; Hahn and Weinberg, 2002). This multi-stage devel-
opment towards an infiltrative tumor is marked by progression of pre-cancerous lesions, also 
termed “cervical intraepithelial neoplasias” (CIN), which are classified according to their grade 
of malignancy: mild dysplasia (CIN I), moderate dysplasia (CIN II) and severe dysplasia (CIN 
III), which still needs years to decades to develop into an invasive tumor (zur Hausen, 2002). 
Precancerous stages often regress, so that only 10% of all cases develop into CIN III and 
maybe to cervical cancer in the long run (Katase et al., 1995). 
Epidemiological and functional studies link cervical carcinomas with the infection of 
high-risk HPVs (human papillomavirus). In addition, further factors contribute to the multi-
stage carcinogenesis process, leaving HPV infection not as the only cause, but definitely as a 
requisite (zur Hausen, 2002). Human papillomaviruses constitute a heterogeneous group of 
more than 100 genotypes that belong to the family of Papovaviridae (de Villiers et al., 2004). 
HPVs infect basal cells of the skin (cutaneous HPV types) or of the mucosa (mucosal HPV 
types). 
Since only a subgroup of the mucosal HPVs is associated with the development of 
more than 90% of the cases of cervical cancer, they are called high-risk HPVs (Dürst et al., 
1983; Boshart et al., 1984). This group is, amongst others, composed of HPV-16 (Dürst et al., 
1983), HPV-18 (Boshart et al., 1984), HPV-31 (Goldsborough et al., 1989), HPV-33 (Cole and 
Streeck, 1986) and HPV-35 (Lorincz et al., 1987). 
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1.1.1. Genomic organization and replication of HPV 
Human papillomaviruses 
are small, non-enveloped, icosa-
hedral viruses containing circular 
genomic DNA of about 8 kbp 
(Favre et al., 1975; Pfister and zur 
Hausen, 1978). The viral genome 
organization is highly conserved 
and can be divided in three differ-
ent regions according to the func-
tion (Danos et al., 1982). 
The URR (upstream regu-
latory region) contains the origin 
of DNA replication, the promoter 
elements driving gene expression 
and the epithelial-specific tran-
scriptional enhancer. Only one of 
the viral transcription factors pos-
sesses a binding site herein. The 
viral protein E2 can either activate 
or repress transcription, depend-
ing on the DNA-status. All other regulators are of cellular origin, e.g. Oct-1, Sp-1, GR, KRF-1, 
YY-1 and AP-1, which is the key regulator of viral transcription (Butz and Hoppe-Seyler, 1993; 
Hoppe-Seyler and Butz, 1994). 
The early region encodes non-structural proteins that are responsible for viral DNA 
replication (E1/E2) (Del Vecchio et al., 1992), transcriptional self-regulation (E2) (Bouvard et 
al., 1994), disruption of cellular cytokeratin network during productive infection (E4) (Doorbar 
et al., 1991) and cellular transformation and immortalization (E5, E6 and E7) (Fehrmann and 
Laimins, 2003). 
The late region codes for the structural proteins (major capsid protein L1 and minor 
capsid protein L2) that are required for capsid assembly (Zhou et al., 1991). 
 
The productive life-cycle of HPV depends on the degree of differentiation of the host 
cell. Through lesions of the outer layers, viruses infect undifferentiated, epithelial cells of the 
basal layer, where the early proteins are expressed (Iftner et al., 1992). Vertical differentiation 
 
Figure 1-1: Genomic organization of human papillo-
maviruses, as exemplified by HPV-18 
The circular genome contains open reading frames for the early 
genes E1-E7 and the late genes L1 and L2. The cis-regulatory 
elements like enhancer, promoter and the origin of replication are 
located in the URR. The interaction of the viral oncogenes E6 and 
E7 with the tumor suppressor proteins p53 and pRB is responsi-
ble for the immortalization of the host cell and represents an im-
portant step towards malignant transformation. 
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of epithelial cells is paralleled by expression of late proteins, which finally results in assembly 
and release of new virus particles. Since virus production and cell lysis is restricted to more 
differentiated cells, viruses are able to persist in an episomal state in the nucleus of their host 
cells for years.  
Additionally, viral DNA can integrate into the host genome. Prior to integration, virus 
DNA is linearized by disruption of the E2 ORF, which leaves L1 and L2 ORFs without pro-
moter. Consequently, virus capsid production is abolished and the trans-repressory effect of 
E2 on the transcription of the viral oncogenes E6 and E7 is abrogated. This leads to an in-
crease in E6 and E7 transcription (Cripe et al., 1987) and subsequently enhances the prolif-
eration rate (von Knebel Doeberitz et al., 1991). Integration into the host genome is consid-
ered to be an early step towards carcinogenesis (zur Hausen, 2002). 
 
 
1.1.2. Viral oncogenes E6 and E7 
The viral oncogenes E6 and E7 are responsible for the transforming capability of high-
risk HPV types, which is achieved through the interaction with cellular tumor suppressor 
genes (Munger and Howley, 2002). 
Besides other proteins, E6 targets p53 that arrests the cell cycle in the event of DNA 
damages to allow DNA repair (Helton and Chen, 2007). High-risk HPV E6 binds to p53 and its 
ubiquitin protein ligase E6-AP, thus triggering degradation of the tumor suppressor protein by 
the proteasome (Werness et al., 1990; Scheffner et al., 1993). This results in an anti-apoptotic 
effect, an accumulation of mutations, chromosomal instability and aneuploidy (Duensing and 
Münger, 2003). Additionally, E6 activates telomerase activity, which contributes to the immor-
talization of the host cell (Klingelhutz et al., 1996). 
High-risk HPV E7 binds to pRb and p107 (Dyson et al., 1989) that normally interact 
with the transcriptional regulator E2F and thus controls expression of growth regulatory genes 
(Goodrich and Lee, 1993). After E7 binding, pRb is degraded and E2F is released from the 
complex. Then, E2F activates its target genes, finally resulting in an increased proliferation 
rate (Bagchi et al., 1990). 
 
 
 
1. Introduction  15 
1.2. The transcription factor AP-1 
The transcription factor AP-1 (activator protein-1) plays a mayor role in many crucial 
processes like proliferation, differentiation, apoptosis and neoplastic transformation (Angel 
and Karin, 1991; van Dam and Castellazzi, 2001; Eferl and Wagner, 2003). In addition, AP-1 
positively or negatively controls the expression of oncogenes of most of the HPV-types, in-
cluding high-risk types HPV-16 and HPV-18, making it an important factor for HPV-induced 
carcinogenesis (Rösl and Schwarz, 1997) (see 1.2.3). 
 
 
1.2.1. Composition of the transcription factor AP-1 
AP-1 stands for a group of dimeric transcription factors that differ in their composition 
of Jun- (c-Jun, JunB and JunD), Fos- (c-Fos, FosB, Fra-1 and Fra-2) and ATF-family mem-
bers (ATF-2, ATF-3 and B-ATF). Jun family members are able to form homodimers or hetero-
dimers with members of the Fos- or ATF-family through a bZIP-motif (basic region leucine zip-
per) (Angel and Karin, 1991; Shaulian and Karin, 2002). 
The expression of single AP-1 proteins is dependent on species, cell type, develop-
mental state and cell cycle phase (Lallemand et al., 1997). Additionally, the repressing or acti-
vating potential of AP-1 is determined by multiple factors: different trans-activating capabilities 
of single AP-1 members, post-translational modifications, interactions with other regulatory 
factors and extra cellular stimuli modulating the abundance of AP-1 subunits, e.g. through dif-
ferential transcriptional rates or mRNA stabilities (Eferl and Wagner, 2003; Hess et al., 2004). 
Thus, AP-1 is able to exert varying functions in the same genomic context. By different homo- 
or heterodimerization patterns, the composition of AP-1 can be very variable. In principle, 
dimerization of Jun- and Fos- family members leads to 18 different combinations (Karin et al., 
1997; Chinenov and Kerppola, 2001). 
AP-1 dimers composed of Jun- and Fos-family members, preferentially bind to an 
asymmetric, heptanucleotide recognition motif, 5’-TGA(G/C)TCA-3’, that is present in promot-
ers of many cellular and viral genes. This AP-1 consensus sequence is termed TRE (TPA (12-
O-tetradecanoylphorbol-13-acetate) responsive element) (Tseng and Verma, 1995). In a com-
plex with ATF-family members, Jun:ATF heterodimers or ATF:ATF homodimers, AP-1 binds 
with higher affinity to the symmetric, octanucleotide CRE-motif (cAMP-responsive element) 
that varies slightly from TRE, 5’-TGACGTCA-3’ (Angel and Karin, 1991; Shaulian and Karin, 
2002; Eferl and Wagner, 2003). 
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c-Jun JunB JunD c-Fos FosB Fra-1 Fra-2 
c-Jun + + + + + + + 
JunB 
 + + + + + + 
JunD 
  + + + + + 
c-Fos 
       
FosB 
       
Fra-1 
       
Fra-2 
       
Table 1-1: Dimer combinations of Jun- and Fos-family proteins 
Only Jun family members are capable of forming dimers among themselves. Fos family members only 
form heterodimers with Jun proteins. 
 
 
1.2.2. AP-1 family members: characteristics, function and regulation 
The two mayor subgroups of AP-1, the Jun- and Fos- families, are characterized by a 
high degree of homology. Binding affinities to TRE- and CRE-motifs, however, are different 
among Jun family members (Ryseck and Bravo, 1991), whereas Fos proteins show different 
trans-activating capabilities. Fos family proteins do not bind to DNA themselves – regulatory 
activity is mediated through a Jun family member. A third family of dimerization partners is the 
ATF family (ATF-2, ATF-3 and B-ATF) that preferentially interacts with CRE rather than TRE 
binding sites (Karin et al., 1997; Chinenov and Kerppola, 2001). 
 
The Jun family is composed of c-Jun, JunB and JunD. Regulation of c-Jun is achieved 
at transcriptional, translational and post-translational levels. c-Jun protein content is set by 
transcriptional and translational control mechanisms, whereas post-translational regulation is 
mainly responsible for rapid responses to stimuli that activate c-Jun. Activation of human c-
Jun is achieved through phosphorylation and dephosphorylation events which control DNA 
binding and transcriptional regulatory activity (Boyle et al., 1991; Pulverer et al., 1991; Franklin 
et al., 1992). 
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First, c-jun promoter is highly conserved and contains potential binding sites including 
Sp-1, nuclear factor-jun, CCAAT transcription factor and AP-1. Induction of human and murine 
c-jun expression is mediated through a TRE-like site located in the proximal region of the 
promoter, which is preferentially recognized by c-Jun:ATF-2 heterodimers (Steinmüller et al., 
2001). Despite this inducible expression, many human (Mechta-Grigoriou et al., 2001) and 
murine (Lamph et al., 1988; Ryder and Nathans, 1988) cell types contain basal levels of c-Jun 
protein prior to stimulation by growth factors, UV irradiation or cytokines. Additionally, human 
phosphorylated c-Jun induces its own transcription through a positive feed-forward loop (Berry 
et al., 2001; Mechta-Grigoriou et al., 2001). 
Second, chicken c-Jun mRNA contains long 5’ and 3’ UTRs (untranslated region) im-
plying additional levels of control (Sehgal et al., 2000). The 5’UTR comprises ~1000nt and is 
characterized by GC-rich sequences, which was shown to generally block efficient translation 
(Kozak, 1989, 1991). Translation, however, is modulated by the presence of an IRES (internal 
ribosomal entry site) allowing translation even under stress conditions when overall protein 
synthesis is reduced (Sehgal et al., 2000). The 3’UTR contains several AUUUA motifs, termed 
AU-rich elements that confer rapid degradation of mRNA (Vogt and Bos, 1990; Aharon and 
Schneider, 1993; Curatola et al., 1995). 
Third, at protein level, c-Jun is unstable with a 90min half-life time that is partially due 
to a PEST motif, which is involved in proteasomal degradation of short-living proteins upon 
ubiquitination. When phosphorylated by JNK (c-Jun N-terminal Kinase) at Ser63, Ser73 and 
Thr91 or Thr93 polyubiquitination was suppressed and consequently the half-life time of murine 
c-Jun was extended (Musti et al., 1997). Contrarily, phosphorylation by GSK-3 (glycogen syn-
thase kinase 3) at Thr239 and Ser243 generates an attachment site for the E3 ligase Fbw7 (F-
box and WD repeat domain containing 7), which targets human c-Jun for polyubiquitination 
and subsequent proteasomal degradation (Wei et al., 2005). 
The JunB promoter contains several putative regulatory elements including a STAT3 
binding site and CRE and SRE (serum response element) recognition sequences. Its biologi-
cal properties differ from c-Jun, since it negatively regulates cell growth. This functional differ-
ence is due to its decreased dimerization potential and the absence of JNK phosphorylation 
sites, what results in a lower trans-activation capacity (Mechta-Grigoriou et al., 2001). 
In contrast to c-jun and junB, junD is unresponsive to serum stimulation and shows 
high basal expression in many cell types. The promoter contains several identified regulatory 
elements: CRE, Sp-1 binding site, octamer motif, CAAT-box and AP-1 consensus site. JunD 
expression is primarily regulated by the octamer motif that is specifically recognized by Oct-1 
(Mechta-Grigoriou et al., 2001). Alternative initiation of translation leads to two predominant 
JunD proteins, a full-length (JunD-FL) and a shorter isoform (∆JunD) (Short and Pfarr, 2002). 
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The Fos family comprises c-Fos, FosB, Fra-1 and Fra-2 that are all immediate early 
genes being rapidly expressed after stimulation. c-Fos protein and mRNA are undetectable in 
most quiescent cells and expression depends on stimulation of hormones, serum mitogens or 
other ligands (Distel and Spiegelman, 1990). Stimulation induces rapid and transient transcrip-
tion of c-fos mediated by several elements, e.g. CRE, SIE (sis-inducible enhancer) and SRE 
(Karin et al., 1997). Additionally, c-Fos is regulated at the level of mRNA stability by AREs 
(adenylate uridylate-rich elements) and mCRD (major protein-coding region determinant of in-
stability). ARE and mCDR elements determine the mRNA turn-over by deadenylation of the 
poly(A) tail and subsequent nuclease digestion of the mRNA body by the exosom (Chen et al., 
1995; Grosset et al., 2000; Chen et al., 2002). Furthermore, c-Fos protein is degraded by the 
ubiquitin-proteasome pathway (Tulchinsky, 2000). 
FosB transcription is rapidly and transiently induced upon stimulation with serum, 
growth factors or phorbol esters like c-fos. However, expression drops below detection levels 
within 3h (Tulchinsky, 2000). 
Transcription of the fosB gene leads to two functionally distinct proteins via alternate 
splicing, FosB and FosB2, of which FosB is larger due to an additional C-terminal domain. 
Functionally, FosB is a more potent transcriptional activator than FosB2 (Skinner et al., 1997; 
Herdegen and Waetzig, 2001; Jochum et al., 2001). 
Fra-1 and fra-2 harbor functional TRE sequences (intronic enhancer of fra-1, promoter 
of fra-2) possibly controlling transcription via a positive auto-regulatory loop. Fra-1 and Fra-2 
lack the C-terminal trans-activation domain, which points towards an inhibitory function that is 
consistent with their delayed de-novo synthesis after stimulation (Tulchinsky, 2000). 
 
 
1.2.3. Role of AP-1 in HPV 
AP-1 binds to two recognition sequences in the URR of HPV, located in the enhancer 
and in the promoter region, thereby positively regulating viral transcription (Hoppe-Seyler and 
Butz, 1994). Upon deletion of one of the two AP-1 recognition sequences, viral transcription is 
greatly diminished (Butz and Hoppe-Seyler, 1993). 
Besides its role as a positive regulator, AP-1 can also inhibit transcription. Antioxidant-
induced changes of the stoichiometry of AP-1 in HPV-16 immortalized keratinocytes were 
paralleled by a selective suppression of E6/E7 transcription (Rösl et al., 1997). Furthermore, a 
shift from predominant c-Jun:c-Jun homodimers to c-Jun:Fra-1 heterodimers upon TNF-α 
treatment lead to a selective reduction of HPV-transcription (Soto et al., 1999). 
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The composition of AP-1 is characteristic for tumorigenic and non-tumorigenic HPV-
positive cell lines and the expression profile of AP-1 members reflects the in vitro and in vivo 
phenotype of the cells. For example, in HPV-immortalized, non-tumorigenic cell lines AP-1 is 
composed of Jun family member homodimers or heterodimers with Fra-1 whereas c-Fos is 
not expressed. Contrarily, tumorigenic HPV16/18 cervix carcinoma cell lines HeLa, SiHa or 
SW756 contain predominantly c-Fos and not Fra-1 leading to Jun:c-Fos heterodimers (O'Hara 
et al., 1987; Soto et al., 1999; Soto et al., 2000; de Wilde et al., 2008). 
In contrast to other AP-1 members, the stoichiometry of Fra-1 and c-Fos in non-
tumorigenic and tumorigenic HPV16/18-positive cell lines shows an inverse correlation. This 
correlation is not only characteristic but determinant for the in vitro and in vivo phenotype of 
HPV-positive cell lines as shown by ectopic overexpression experiments. Overexpression of 
c-fos in a non-tumorigenic HPV18-positive cell line shifted the balance from Jun:Fra-1 dimers 
to Jun:c-Fos dimers. As a result, cells underwent morphological changes in vitro and gained 
the capability of tumor formation in immuno-suppressed mice in vivo (Soto et al., 1999). Con-
trarily, ectopic overexpression of fra-1 in tumorigenic HPV18-positive cells did not affect the 
stoichiometry of AP-1 dimers and did not reverse the tumorigenic phenotype probably be-
cause of different phosphorylation marks (De-Castro Arce, 2003). 
 
 
Figure 1-2: Phenotype-dependent composition of AP-1 in HPV-positive cell lines 
Constitutive expression of c-fos induces tumorigenic transformation of HPV-immortalized cells. 
Fra-1 expression is a marker for a non-tumorigenic phenotype, but can not revert tumorigenicity. 
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1.3. microRNAs 
MicroRNAs or miRNAs were first discovered in 1993. It could be shown that a 22nt 
RNA, termed lin-4, is required for the appropriate timing of post-embryonic development in 
Caenorhabditis elegans (Lee et al., 1993; Wightman et al., 1993). Since then, miRNAs have 
been identified in diverse animals and also plants. miRNAs form a family of noncoding small 
RNAs of 20-24nt in length, regulating the expression of protein-coding genes post-
transcriptionally. This is achieved by regulating mRNA translation or stability in the cytoplasm 
(Bartel, 2004). Thereby, miRNAs are involved in crucial processes, including development, dif-
ferentiation, apoptosis and proliferation. Current estimates suggest that about 30% of human 
mRNAs are conserved miRNA targets (Lewis et al., 2005) that are regulated by predicted 
~1000 different miRNAs, many of which are also conserved in other vertebrates (Bentwich et 
al., 2005; Berezikov et al., 2005). This makes miRNAs the most abundant class of regulatory 
genes. Each vertebrate miRNA targets about 200 transcripts and multiple miRNAs can syner-
gistically regulate one single target (Krek et al., 2005; Tay et al., 2008). 
Target sites are mainly localized in the 3’UTR (untranslated region) of mRNAs. There 
are, however, studies reporting target sites in the coding region (Duursma et al., 2008; Tay et 
al., 2008) and in the 5’UTR of mRNAs (Orom et al., 2008). The exact mechanism how target 
mRNAs are repressed is not fully deciphered, yet. Indeed, there are several models (see 
1.3.3). 
 
 
1.3.1. Biogenesis of microRNAs 
Genes encoding miRNAs are mostly transcribed by RNA polymerase II (Pol II) (Cai et 
al., 2004; Lee et al., 2004) and less by Pol III (Borchert et al., 2006). miRNA genes can be 
categorized according to their genomic location. 
First, miRNAs can be encoded in introns, e.g. miR-135b in intron 1 of the TU 
ENSESTG0000000249 (transcription unit) (Rodriguez et al., 2004), and also in exons of non-
protein-coding transcripts, e.g. miR-155 in exon 3 of BIC (B-cell integration cluster) (Tam, 
2001). Second, miRNAs can be part of protein-coding genes, e.g. miR-21 in intron 10 of 
TMEM49 (transmembrane protein 49) (Fujita et al., 2008) or, as the only representative so far, 
miR-650 in the leader exon of the IGVL gene (immunoglobulin lambda variable region gene) 
(Das, 2009). In addition, miRNAs are encoded by individual genes or by clusters of genes ex-
pressing a polycistronic transcript, e.g. miR-17-92 cluster (Lee et al., 2002). 
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Transcription by Pol II 
leads to capped, polyade-
nylated primary transcripts 
(pri-miRNAs) that are normally 
several kilo bases long and 
that embody local stem-loop 
hairpin structures of 60-110nt 
(see Fig. 1-2). These stem-
loops are cleaved in the nu-
cleus during the first step of 
miRNA maturation. The liber-
ated product, the small hair-
pin, is named precursor 
miRNA (pre-miRNA) (Lee et 
al., 2002). This cleavage is 
processed by the nuclear 
RNase III-type protein Drosha 
and its cofactor DGCR8 (Di-
George syndrome critical re-
gion gene 8 protein) forming 
together the microprocessor 
complex (Gregory et al., 2004; Han et al., 2004). Alternatively, Ruby et al. found intronic 
miRNA precursors, termed mirtrons that bypass Drosha processing in Drosophila 
melanogaster and Caenorhabditis elegans (Ruby et al., 2007). Instead of stem-loop formation, 
which is needed for pri-miRNA cleavage by Drosha (Han et al., 2006), introns have conserved 
canonical splice sites and are dependent on a functional splicing and debranching pathway 
and not on Drosha processing. After splicing, mirtrons fold into the characteristic hairpin pre-
miRNA structure and enter the common biogenesis pathway. Compared to flies and nema-
todes, mammals have few pre-miRNA-sized mirtrons (Lim and Burge, 2001; Yandell et al., 
2006),which might explain why mirtrons have not yet been found among the annotated mam-
malian miRNAs (Griffiths-Jones, 2004). 
After nuclear cleavage, pre-miRNAs are exported to the cytoplasm (Yi et al., 2003) by 
exportin 5, which belongs to the nuclear transport receptor family (Bohnsack et al., 2004; Lund 
et al., 2004; Yi et al., 2005). Following export from the nucleus, pre-miRNAs are cleaved near 
the terminal loop by the cytoplasmic RNase III-type protein Dicer, releasing ~22nt miRNA du-
plexes (Bernstein et al., 2001; Hutvágner et al., 2001). 
 
Figure 1-3: Biogenesis of miRNAs (Filipowicz et al., 2008) 
For details see chapter 1.3.1 
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After Dicer cleavage, one strand of the resulting ~22nt dsRNA is loaded into the effec-
tor complex. Two sorts of effector complexes can be distinguished depending on composition 
and mode of action: miRISC (miRNA induced silencing complex) and miRNP (miRNA ribonu-
cleoprotein complex), see 1.3.2. Since only one strand represents the mature and active 
miRNA (also termed “guide strand”), the complementary strand (also termed “passenger 
strand”) is degraded. The thermodynamic stability of the two ends of the duplex determines 
strand selection (Khvorova et al., 2003; Schwarz et al., 2003). This process, however, is not 
yet fully understood since some hairpins produce miRNAs from both strands in equal 
amounts. The core component of the effector complexes is an Ago protein (Argonaute) that 
exercises miRNA-mediated repression. The Ago protein family consists of four members, 
Ago1-4, that, however, do not differ by the set of miRNAs they bind to (Meister et al., 2004; 
Azuma-Mukai et al., 2008). 
 
 
1.3.2. Repression mechanisms of miRNAs 
Mechanisms by which miRNAs repress their respective target mRNAs can be divided 
into two groups, depending on the degree of complementarity with their targets (see Fig. 1-3). 
miRNAs exhibiting a nearly perfect degree of complementarity with their target mRNA se-
quences trigger endonucleolytic cleavage by Ago2 in an RNAi-like mechanism (Meister et al., 
2004). Ago2 is the core component of the effector complex miRISC (miRNA induced silencing 
complex). 
In most cases, however, miRNAs pair imperfectly with the mRNA due to central mis-
matches. In this case, target recognition is achieved through perfect base pairing between a 
“seed” sequence located at positions 2-7 in the miRNA sequence and target sequences in the 
mRNA (Brennecke et al., 2005). Although less important, 3’end pairing might contribute to tar-
get recognition, especially when seed-pairing is weaker. Besides, functional miRNA sites not 
following the “seed-rule” are also reported (Stern-Ginossar et al., 2007; Orom et al., 2008). 
Imperfect pairing of miRNA:mRNA duplexes leads to post-transcriptional repression, which 
can be mediated by all four Ago proteins, Ago1-4. Repression is mediated by the effector 
complex miRNP (miRNA-ribonucleoprotein complex) that does not primarily involve endonu-
cleolytic cleavage. Contrarily, target mRNAs are transported to P-bodies, where translation is 
repressed by different mechanisms: 
(1) block of initiation. The central domain of Ago proteins contains limited sequence 
homology to the cap-binding region of eIF4E (Kiriakidou et al., 2007), which is a subunit of the 
eukaryotic translation initiation complex. It was shown that Ago proteins can compete with 
eIF4E for m7G binding and thus repress translation at the initiation step. Additionally, decap-
1. Introduction  23 
ping by the Dcp1-Dcp-2 complex leaves the mRNA susceptible for 5’3’ decay (Lykke-
Andersen, 2002; van Dijk et al., 2002). 
(2) post-initiation repression. Ago proteins interact with the P-body protein GW182 
(Jakymiw et al., 2005; Liu et al., 2005), which is thought to recruit the CCR4-NOT deadenylat-
ing complex (Behm-Ansmant et al., 2006). Partial deadenylation of mRNAs is a necessary 
step of P-body formation (Zheng et al., 2008) and of subsequent mRNA decay (Chen and 
Shyu, 1995; Chen et al., 1995; Chen and Shyu, 2003; Parker and Song, 2004; Wu et al., 
2006). Target mRNAs with shortend poly(A) tails are then further deadenylated and finally de-
graded by the exosome, 3’5’ direction (Yamashita et al., 2005). 
 
 
Figure 1-4: Repression mechanism of miRNAs 
Modified according to (Filipowicz et al., 2008), for details see chapter 1.3.2 
 
 
1.3.3. microRNAs and cancer 
It is well known that carcinogenesis is marked by a broad deregulation of normally fine-
tuned genes, what can even be used to classify different types of cancers (Ramaswamy et al., 
2001; Su et al., 2001). Of those genes, protein-coding oncogenes and tumor suppressor 
genes are of particular interest. Due to their role in post-transcriptional gene regulation, 
miRNAs have been viewed as potential oncogenes or tumor suppressor genes and were thus 
studied in the context of tumorigenicity. 
Many high-throughput expression profiling studies were conducted for different types 
of cancers (Michael et al., 2003; Calin et al., 2004a; Iorio et al., 2005) that state the same ob-
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servation: global deregulation and global down regulation of miRNAs in tumor versus normal 
tissues. 
Deregulation is not surprising since miRNA expression patterns are highly specific for 
cell-type and cellular differentiation status (Aravin et al., 2003; Bernstein et al., 2003; Abbott et 
al., 2005). Cancer cells, undergoing malignant transformation, differ in phenotype and differ-
entiation status from healthy surrounding tissue by e.g. acquiring the capability to evade apop-
tosis, to loose contact-inhibition, to be resistant to anti-growth signals or to sustain neoangio-
genesis (Hanahan and Weinberg, 2000). A deregulated miRNA expression profile can then be 
cause and / or consequence of this event. 
Furthermore, the second finding that miRNAs are largely down regulated supports the 
idea on an altered differentiation status. Undifferentiated embryonic cells also express low 
levels of miRNAs; the increase of miRNA expression parallels the start of the differentiation 
process (Wienholds et al., 2005). A possible disturbance of the miRNA processing machinery 
(Dicer, Drosha, Ago2 and DGCR8) as an obvious reason for reduced miRNA levels was not 
found in cancer cells (Lu et al., 2005). 
Since the expression profile of miRNAs is so specific, it is likely that much of the al-
tered miRNA expression is a secondary effect of the loss of cellular identity that accompanies 
malignant transformation. Thus, up- or down regulation of a miRNA in a certain tumor-type is 
not necessarily indicative of a causative role in tumorigenesis. Nevertheless, data obtained 
from profiling studies can be used to classify human cancers according to the developmental 
lineage, differentiation state and the distinct mechanism of transformation of the tumor 
(Pavlidis and Fizazi, 2005).Classification based on expression data of miRNAs was even 
found to be superior to those of mRNAs (Lu et al., 2005). 
To address the question, if certain miRNAs play a causative role in carcinogenesis, the 
same criteria of protein-coding oncogenes or tumor suppressor genes, must be applied. Four 
types of evidence should be at least partially fulfilled by a miRNA before it can surely be 
viewed as a tumor suppressor or oncogene (Kent and Mendell, 2006): (1) data showing wide-
spread deregulation in different cancers, (2) gain or loss of miRNA function, (3) direct docu-
mentation of tumor-suppressing or tumor-promoting activity using animal models, and (4) the 
identification of cancer-relevant target genes that depict mechanisms through which a miRNA 
contributes to oncogenesis. 
A few miRNAs that partially or completely fulfill these criteria were already described. 
Known tumor suppressor miRNAs are the let-7 family, repressing, amongst others, RAS on-
cogene (Johnson et al., 2005).Reduced expression of let-7 was linked to poor survival of lung 
cancer patients (Takamizawa et al., 2004; Yanaihara et al., 2006). Further tumor suppressors 
are miR15a and miR-16-1 that target BCL2 (B-cell CLL/lymphoma 2) (Cimmino et al., 2005) 
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and that are frequently deleted in CLL (chronic lymphocytic leukemia), mantle cell lymphoma 
and multiple myeloma (Calin et al., 2002; Calin et al., 2005) and in prostate cancer (Dong et 
al., 2001). Down-regulation of miR-143/-145 was observed in several cancer types: colorectal 
cancer (Michael et al., 2003), breast cancer (Iorio et al., 2005) and myelodysplastic syndrome 
(Calin et al., 2004b). In smooth muscle cells, it was shown that miR-143/-145 synergistically 
target a network of transcription factors including Klf4 (Kruppel-like factor 4), myocardin and 
Elk-1, which represses proliferation (Cordes et al., 2009). 
Besides, oncogenic miRNAs, also termed “oncomirs”, have been found to be up-
regulated in various tumors. Levels of miR-155 are increased in B-cell lymphoma and Burkitt 
lymphomas (Eis et al., 2005), papillary thyroid carcinoma (He et al., 2005a) and in breast, lung 
and colon cancer (Volinia et al., 2006). miR-155 negatively regulates AT1R (angiotensin II re-
ceptor, type 1) (Martin et al., 2006), which plays a mayor role in fluid homeostasis, and it can, 
similarly to c-myc, induce oncogenesis in chicken embryonic fibroblasts (Tam et al., 2002). 
The miR17-92 cluster, which comprises the six miRNAs, miR-17, -18a, -19a, -19b-1, -20a and 
-92-1, targets, amongst others, E2F1 (E2F transcription factor 1) (O'Donnell et al., 2005) and 
the tumor suppressor PTEN (phosphatase and tensin homolog) (Lewis et al., 2003). The clus-
ter is up-regulated in B-cell lymphoma (Ota et al., 2004; He et al., 2005b), lung cancer 
(Hayashita et al., 2005; Volinia et al., 2006) and in breast, colon, pancreas and prostate can-
cer (Volinia et al., 2006). Lastly, the oncogenic miRNA miR-21 possesses anti-apoptotic prop-
erties in glioblastomas (Chan et al., 2005) and is also up-regulated in breast, colon, lung, pan-
creas, stomach and prostate cancer (Volinia et al., 2006). 
 
 
1.3.4. microRNAs and cervical cancer 
Several studies have been published on the relation of microRNAs and HPV-infection 
or cervical cancer. Mostly, they report the (deregulated) expression of miRNAs and early func-
tional studies with the overexpression or inhibition of single miRNAs. But, except for one 
study, respective target genes have not been identified, yet. 
In contrast to other pathogenic DNA viruses that are known to express miRNAs 
(polyomavirus SV40, adenovirus hAV, herpesviruses) (Andersson et al., 2005; Grey et al., 
2005; Pfeffer et al., 2005; Sullivan et al., 2005; Aparicio et al., 2006), human papillomaviruses 
do not express miRNAs (Pfeffer et al., 2005; Cai et al., 2006; Lui et al., 2007). 
miRNA array expression studies were conducted reporting deregulation of miRNAs in 
cervical carcinoma cell lines (Lui et al., 2007; Martinez et al., 2008), in cervical cancer cell 
lines and tissues (Wang et al., 2008b) and in early stage ISCCs (invasive squamous cell car-
1. Introduction  26 
cinomas) (Lee et al., 2008). Down regulation of miR-143, which is reported in other types of 
cancer, was also observed in cervical cancer (Lui et al., 2007; Wang et al., 2008b). Further-
more, some miRNAs were analyzed for their physiological effects in cervical cancer cell lines, 
e.g. knockdown of miR-199a suppressed cell growth in vitro, which was potentiated by the 
anticancer drug cisplatin (Lee et al., 2008). Overexpression of miR-143 and miR-145 had a 
growth suppressive effect, whereas overexpression of miR-146a increased cell proliferation 
(Wang et al., 2008b). Targets for miR-143, -145, -146a and -199a were not found. Contrarily, 
miR-218 and its host-gene, SLIT2 tumor suppressor gene, were characterized in more detail. 
High-risk, but not low-risk, E6 protein reduced the expression of miR-218 and SLIT2, which 
lead to the up-regulation of LAMB3 (laminin-5 β3 protein), a target of miR-218. The binding 
site of miR-218, however, was not verified (Martinez et al., 2008). Since LAMB3 is known to 
increase cell migration and tumorigenicity (Dajee et al., 2003; Calaluce et al., 2004), down 
regulation of miR-218 by high-risk HPV E6 and consequential up regulation of LAMB3 con-
tributes to tumorigenesis. 
Furthermore, HPV-infected cell lines expressed a different set of miRNAs, when they 
were grown in organotypic raft culture instead of monolayer cell culture. The miRNA expres-
sion profile was changed during the differentiation process; however, it was not altered by the 
status of the HPV genome, integrated or episomal (Wang et al., 2008b). 
Interestingly, Drosha, located at 5p13.3, was the most significantly up-regulated tran-
script in a study showing the gain of chromosome 5 in cervical SCCs (squamous cell carcino-
mas) and SILs (squamous intraepithelial lesions) (Muralidhar et al., 2007). Drosha overex-
pression resulted in a differential regulation of a subset of miRNAs, some of which are also 
reported to be deregulated in other cancer types. 
 
 
1.3.5. microRNAs and AP-1 
AP-1 can potentially regulate the expression of miRNAs by acting as a transcriptional 
activator or repressor. On the other hand, AP-1 family members can theoretically also be sub-
jected to miRNA-mediated regulation. 
So far, c-Fos is the only subunit of AP-1 that is reported to be regulated by miRNAs. It 
was shown that miR-7b, which is over expressed in the hypothalamus of mice after hyperos-
molar stimulation, inhibits c-Fos translation with no effect on c-Fos mRNA levels (Lee et al., 
2006). The search engine miRanda predicted two putative target sites of miR-7b in the 3’UTR 
of c-Fos that are both conserved among mammalian species. If both or only one of the puta-
tive sites is a true binding site for miR-7b, remains to be determined. Secondly, it was pub-
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lished that miR-101 represses the expression of c-Fos oncogene (Li et al., 2009). miRNA ex-
pression profiling of human hepatocellular carcinomas compared to surrounding normal tis-
sues revealed down-regulation of miR-101. In the 3’UTR of c-Fos, the search engine Target-
Scan predicted one putative binding site, which is conserved among many species. By muta-
tion experiments, the putative target site was confirmed to be a true binding site for miR-101. 
Besides being a target of miRNAs, AP-1 can also regulate the expression of miRNAs. 
RAS oncogene activity can be found in a variety of tumor types, e.g. in adenocarcinomas of 
the pancreas (90%), the colon (50%), and the lung (30%) (Bos, 1989). The induction of AP-1 
activity by RAS and RAS-dependent AP-1-compositional changes are described in various 
cell systems (Mechta et al., 1997; Casalino et al., 2003). In a rat thyroid cell line, the overex-
pression of RAS induced differential expression of AP-1 subunits such as Fra-1 (Talotta et al., 
2009). Newly-expressed Fra-1 containing dimers activated the expression of miR-21 through 
three AP-1 responsive elements in its promoter. Among the target genes of miR-21 is the tu-
mor suppressor PDCD4 that, in turn, inhibits AP-1 activity (Yang et al., 2003; Wang et al., 
2008a). This constitutes an auto-regulatory loop in which miR-21 is a direct target and an indi-
rect regulator of AP-1. The finding of this circuit was further confirmed by a study of vascular 
smooth muscle cells (Lin et al., 2009). 
Furthermore, AP-1 dimers are also reported to bind to the promoter of BIC (B-cell inte-
gration cluster), which constitutes the pri-miRNA of miR-155 (Yin et al., 2008). During B-cell 
maturation, transcription of the oncogenic miRNA-155 is activated via ERK and JNK signaling 
pathways. JunB:FosB dimers were shown to be recruited to a conserved AP-1 site in the pro-
moter. 
 
 
1.4. Aim of this study 
The transcription factor AP-1 plays a decisive role in HPV-induced carcinogenesis, 
since it positively or negatively regulates transcription of the viral oncogenes E6 and E7. Be-
sides, the composition of AP-1 is an important marker of the in vitro and in vivo phenotype of 
HPV-positive cells. miRNAs are potent post-transcriptional regulators of protein-coding genes 
and are known to enhance and cause transformation. Deregulated miRNA expression might 
contribute to an altered dimerization pattern of AP-1 during carcinogenesis. 
 
This study wants to decipher and characterize miRNAs that regulate AP-1 proteins and 
that are potentially differentially regulated in non-tumorigenic and tumorigenic cells. 
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2. Material 
2.1. Chemicals and reagents 
[γ-32P] dATP 10mCi/ml Amersham-Pharmacia, Braunschweig 
Acrylamide/bis-Acrylamide (29:1), 30% (v/v) Sigma, Deisenhofen 
Agarose Invitrogen, Karlsruhe 
Boric acid Sigma, Deisenhofen 
BSA (Albumin bovine Fraction V) BIOMOL, Hamburg 
Bradford-Reagent Bio-Rad Laboratories, Munich 
Bromophenol blue Serva Feinbiochemica, Heidelberg 
Chloroform Merck, Darmstadt 
DEPC Sigma, Deisenhofen 
DTT Sigma, Deisenhofen 
DMSO Merck, Darmstadt 
E-64 Roche Diagnostics, Mannheim 
ECL-Reagent NEN Lifescience Products, Cologne 
EDTA Roche Diagnostics, Mannheim 
EGTA Sigma, Deisenhofen 
Ethanol absolute Merck, Darmstadt 
Ehtidium bromide solution, 1% Fluka BioChemika, Gillingham (UK) 
ExpressHyb™ Hybridization Solution Clontech, Mountain View, CA (USA) 
Formaldehyde Merck, Darmstadt 
Formamide Fluka BioChemika, Deisenhofen 
Glycerin, 86% Merck, Darmstadt 
Glycine Sigma, Deisenhofen 
Glycogen, 20µg/µl Roche Diagnostics, Mannheim 
HEPES Gerbu, Gaiberg 
Hydrochloric acid Merck, Darmstadt 
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Isoamyl alcohol Merck, Darmstadt 
Magnesium chloride Merck, Darmstadt 
2-Mercaptoethanol Sigma, Deisenhofen 
Methanol Merck, Darmstadt 
Milk powder Carl Roth, Karlsruhe 
MOPS Gerbu, Karlsruhe 
Nonidet® P-40 (NP-40), 10% (w/v) Roche Diagnostics, Mannheim 
dNTPs Invitrogen, Karlsruhe 
PBS Gibco, Eggenstein 
Pefabloc SC Roche Diagnostics, Mannheim 
PMSF Sigma, Deisenhofen 
Poly(dI-dC).poly(dI-dC) Amersham-Pharmacia, Freiburg 
Potassium chloride Merck, Darmstadt 
2-Propanol Merck, Darmstadt 
Random primers p(dN)6 Boehringer, Mannheim 
RNasin Plus RNase Inhibitor, 40 U/µl Promega, Mannheim 
Roti-Phenol, pH 4.0 Carl Roth, Karlsruhe 
Sigmacote, SL2 Sigma-Aldrich, St. Louis, MO (USA) 
Sodium acetate Merck, Darmstadt 
Sodium citrate Sigma, Deisenhofen 
Sodium chloride Merck, Darmstadt 
Sodium dodecyl sulfate Sigma, Deisenhofen 
Sodium fluoride Merck, Darmstadt 
Sodium hydroxide Carl Roth, Karlsruhe 
Sodium ortho-vanadate Sigma, Deisenhofen 
TEMED Gibco Life Technologies, Carlsbad, CA (USA) 
TRIS Sigma, Deisenhofen 
Trypan blue Sigma, Deisenhofen 
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Tween® 20 Sigma, Deisenhofen 
Urea Merck, Darmstadt 
Xylene cyanol Serva Feinbiochemica, Heidelberg 
 
 
2.2. Reagents and media for bacteria culture 
Ampicillin Roche Diagnostics, Mannheim 
Bacto™ Agar Becton Dickinson, Heidelberg 
Kanamycin BIOTREND Chemikalien, Cologne 
LB-Medium (Lennox) Carl Roth, Karlsruhe 
S.O.C. Medium Invitrogen, Karlsruhe 
 
 
2.3. Reagents and media for cell culture 
DMEM + GlutaMAX™-I 
cat #21885, lot #514126 
Invitrogen, Karlsruhe 
OPTI-MEM® –I 
cat #11058, lot# 492516 
Invitrogen, Karlsruhe 
Tet System approved FBS 
cat #631106, lot #6B0314 
Clontech, Mountain View, CA (USA) 
Pen Strep 
cat #15140, lot #577998 
+10,000U/ml Penicillin 
+10,000µg/ml Streptomycin 
Invitrogen, Karlsruhe 
0.25% Trypsin-EDTA 
cat #25300, lot #578150 
Invitrogen, Karlsruhe 
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2.4. Oligonucleotides 
2.4.1. siRNAs and miRIDIAN® miRNA mimics for knock-down experiments 
siRNA Sequence Manufacturer Reference 
siDrosha 5’-TGTCATATAAGTCACGAAGCCTA-3’ 
processed from shRNA sequence 
Dharmacon, 
Chicago 
(Aagaard et al., 
2007) 
siDicer 5’-AAGGCTTACCTTCTCCAGGCT-3’ Dharmacon, 
Chicago 
(Tang et al., 2007) 
siLuciferase 5’-CGTACGCGGAATACTTCGATT-3’ Dharmacon, 
Chicago 
(Elbashir et al., 
2001) 
siScramble 5’-AACAGTCGCGTTTGCGACTGG-3’ Dharmacon, 
Chicago 
(Schneider et al., 
2006) 
miR-495 miRIDIAN Mimic 
cat # C-300762-05-0005 
Dharmacon, 
Chicago 
 
let-7a miRIDIAN Mimic 
cat # C-300475-05-0005 
Dharmacon, 
Chicago 
 
miRIDIAN 
Mimic 
Negative 
control #1 
5’-UCACAACCUCCUAGAAAGAGUAGA-3’ 
cat # CN-001000-01-05 
Dharmacon, 
Chicago 
 
All siRNAs were synthesized with processing option A4 and ordered with a dTdT overhang at 
the 3’ end. 
 
 
2.4.2. double-stranded oligonucleotides for gene analysis by EMSA 
Oligo Sequence Origin Reference 
AP-1 consensus 5’-cgcttgatgactcagccggaa-3’ Collagenase gene (Lee et al., 1987) 
Oct-1 consensus 5’-tgtcgaatgcaaatcactagaa-3’  (Scheidereit et al., 1988) 
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2.4.3. Single-stranded oligonucleotides as Northern probes for miRNA analysis 
Probe Sequence 
has-let-7a 5’-aactatacaacctactacctca-3’ 
5S 5’-ttagcttccgagatcagacga-3’ 
 
 
2.4.4. Oligonucleotides for protein-coding gene analysis by RT-PCR 
Gene Sequence TA Size Reference 
atf-2 F 5’-ctccagctcacacaactcca-3’ 
R 5’-tgtttcagctgtgccacttc-3’ 
55°C 247 bp  
dicer1 F 5’-ggtccaccaatgagctgtgt-3’ 
R 5’-ctttcccaactggcatcaaa-3’ 
53°C 112 bp  
drosha F 5’-catgcaccagattctcctgta-3’ 
R 5’-gtctcctgcataactcaactg-3’ 
57°C 267 bp  
c-fos F 5’-aacttcattcccacggtcac-3’ 
R 5’-ccttctccttcagcaggttg-3’ 
55°C 397 bp (De-Castro Arce  et 
al., 2004) 
fosB F 5’-gggaacgaaataaactagca-3’ 
R 5’-aaactccagacgttccttct-3’ 
51°C 154 bp  
fra-1 F 5’-gcgcctaggccttgtatctccctttcccc-3’ 
R 5’-ccgctcgaggcgaggagggttggagagcc-3’ 
61°C 212 bp (De-Castro Arce  et 
al., 2004) 
fra-2 F 5’-gctgtagtggtgaaacagga-3’ 
R 5’-aggataggtgaagacgaggt-3’ 
55°C 203 bp  
gapdh F 5’-tggatattgttgccatcaatgacc-3’ 
R 5’-gatggcatggactgtggtcatg-3’ 
65°C 461 bp (Griffiths  et al., 
1997) 
jdp2 F 5’-agcccgtgaaaagtgagcta-3’ 
R 5’-cagtgggttgccttctgact-3’ 
55°C 284 bp  
c-jun F 5’-tcgacatggagtcccagga-3’ 
R 5’-cgagttctgagctttcaagg-3’ 
57°C 143 bp  
junB F 5’-cgactcatacacagctacgg-3’ 
R 5’-gagccctgaccagaaaagta-3’ 
57°C 186 bp  
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junD F 5’-ggtgcccgacgtgccgagctt-3’ 
R 5’-gtacgccgggacctggtgc-3’ 
61°C 307 bp (De-Castro Arce  et 
al., 2004) 
net F 5’-acccaaaggcttggaaatct-3’ 
R 5’-agtgtggggaactggaacag-3’ 
53°C 258 bp (Hitschler, 2007) 
oct-1 F 5’-agccaaactaccatctctcg-3’ 
R 5’-cacacggatgttggtctcta-3’ 
55°C 213 bp  
Newly designed primers were chosen with Primer3 (http://frodo.wi.mit.edu/). 
 
 
2.4.5. Oligonucleotides for miRNA analysis by RT-PCR 
Gene Sequence TA Size Cycles 
hsa-miR-32 F 5’-ggagatattgcacattactaagt-3’ 
R 5’-gaaaatatcacacacactaaattg-3’ 
57°C 70 bp 35 
hsa-miR-92-1 F 5’-ctttctacacaggttgggatc-3’ 
R 5’-ccaaactcaacaggccggg-3’ 
57°C 78 bp 35 
hsa-miR-340 F 5’-ttgtacctggtgtgattataaag-3’ 
R 5’-taagataccaggtatggctataa-3’ 
57°C 95 bp 35 
hsa-miR-495 F 5’-tggtacctgaaaagaagttgc-3’ 
R 5’-tgataccgaaaaagaagtgcac-3’ 
57°C 82 bp 35 
hsa-let-7a-3 F 5’-gggtgaggtagtaggttgta-3’ 
R 5’-aggaaagacagtagattgtatag-3’ 
57°C 74 bp 35 
 
 
2.4.6. Oligonucleotides for 3’UTR cloning by RT-PCR 
Gene Primer sequence TA Size 
Without linkers, full-length 3’UTR:   
Jun 3’UTR F 5’-ggtgccaactcatgctaacg-3’ 
R 5’-ttggtatttgaatacatttattgtga-3’ 
59°C 1299 bp 
Oct-1 3’UTR F 5’-gcacagtgagctgggcaga-3’ 
R 5’-aatttttggttagaaagttctcca-3’ 
57°C 286 bp 
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With linkers, full-length 3’UTR:   
Dicer 3’UTR F 5’-agggcgatcgcctcgagtagctgaaaccgctttttaaaat-3’ 
R 5’-cgtgcggccgcgtttaaacgaacagacgataactttattgg-3’ 
55°C 4312 bp 
Fra-1 3’UTR F 5’-agggcgatcgcctcgagtcgctttgtgaggcgcctga-3’ 
R 5’-cgtgcggccgcgtttaaaccacagcttcaagccttttattc-3’ 
57°C 712 bp 
c-Jun 3’UTR F 5’-agggcgatcgcctcgagacattttgaagagagaccgtcg-3’ 
R 5’-cgtgcggccgcgtttaaacttggtatttgaatacatttattgtga-3’ 
57°C 1329 bp 
Net 3’UTR F 5’-agggcgatcgcctcgagaaatcctgatgacgtctggcc-3’ 
R 5’-cgtgcggccgcgtttaaactcgatgtttattgtctaaatatgg-3’ 
57°C 696 bp 
Oct-1 3’UTR F 5’-agggcgatcgcctcgaggcacagtgagctgggcaga-3’ 
R 5’-cgtgcggccgcgtttaaacaatttttggttagaaagttctcca-3’ 
57°C 322 bp 
With linkers, single segments:   
Fra-1 3’UTR Seg 1 F 5’-agggcgatcgcctcgagtcgctttgtgaggcgcctga-3’ 
R 5’-cgtgcggccgcgtttaaactagggctccagaggacctct-3’ 
59°C 326 bp 
Fra-1 3’UTR Seg 2 F 5’-agggcgatcgcctcgagagactttgtagatccttagagg-3’ 
R 5’-cgtgcggccgcgtttaaacagctgtgcggttcaggagg-3’ 
59°C 216 bp 
Fra-1 3’UTR Seg 3 F 5’-agggcgatcgcctcgagaggtgattggaccaggccatt-3’ 
R 5’-cgtgcggccgcgtttaaaccacagcttcaagccttttattc-3’ 
59°C 219 bp 
c-Jun 3'UTR Seg 1 F 5’-agggcgatcgcctcgagacattttgaagagagaccgtcg-3’ 
R 5’-cgtgcggccgcgtttaaaccctttaatactgaatgagatcgaa-3’ 
55°C 351 bp 
c-Jun 3’UTR Seg 2 F 5’-agggcgatcgcctcgaggaactgcatggacctaacattc-3’ 
R 5’-cgtgcggccgcgtttaaacactcagagtgctccaaatctct-3’ 
 
55°C 360 bp 
c-Jun 3’UTR Seg 3 F 5’-agggcgatcgcctcgagccagtgttgtttgtaaataagag-3’ 
R 5’-cgtgcggccgcgtttaaacgtccctctccactgcaacc-3’ 
55°C 414 bp 
c-Jun 3’UTR Seg 4 F 5’-agggcgatcgcctcgaggtttcaggaggctggaggaa-3’ 
R 5’-cgtgcggccgcgtttaaacttggtatttgaatacatttattgtga-3’ 
55°C 295 bp 
 
 
2. Material  35 
2.4.7. Oligonucleotides for sequencing 
Primer Primer sequence 3’UTRs 
Check2 Seq F 5’-gaaggtgaagggcctccactt-3’ c-Jun, Fra-1, Net, Oct-1, Dicer 
dicer1 Seq 1 F 5’-atgatctttggctaaacaccc-3’ Dicer 
dicer1 Seq 2 F 5’-taattccgatttggaaccttag-3’ Dicer 
dicer1 Seq 3 F 5’-aagcattgcacttggtaccat-3’ Dicer 
 
 
2.5. Plasmids 
2.5.1. Original plasmids 
Plasmid Insert Reference 
pAP-1-Luc, (pTRE-Luc) (TRE)-Firefly luciferase Stratagene 
pRL-TK (HSV-TK)-Renilla luciferase Promega 
psiCHECK™-2 (SV40)-Renilla luciferase 
(HSV-TK)-Firefly luciferase 
Promega 
pCR2.1-TOPO-GAPDH (promoter less)-GAPDH Dr. Bachmann 
Laboratory Prof. Dr. Rösl 
The promoter of each expression plasmid is mentioned in brackets. 
 
 
2.5.2. Modified plasmids 
Plasmid Insert 
psiCHECK-2-c-Jun 3’UTR Fusion mRNA: Renilla luciferase - 3’UTR of c-Jun 
psiCHECK-2-Fra-1 3’UTR Fusion mRNA: Renilla luciferase - 3’UTR of Fra-1 
psiCHECK-2-Net 3’UTR Fusion mRNA: Renilla luciferase - 3’UTR of Net 
psiCHECK-2-Dicer 3’UTR Fusion mRNA: Renilla luciferase - 3’UTR of Dicer 
psiCHECK-2-Oct-1 3’UTR Fusion mRNA: Renilla luciferase - 3’UTR of Oct-1 
psiCHECK-2-c-Jun seg 1 Fusion mRNA: Renilla luciferase - 1st segment of c-Jun 3’UTR 
2. Material  36 
psiCHECK-2-c-Jun seg 2 Fusion mRNA: Renilla luciferase - 2nd segment of c-Jun 3’UTR 
psiCHECK-2-c-Jun seg 3 Fusion mRNA: Renilla luciferase - 3rd segment of c-Jun 3’UTR 
psiCHECK-2-c-Jun seg 4 Fusion mRNA: Renilla luciferase - 4th segment of c-Jun 3’UTR 
psiCHECK-2-ra-1 seg 1 Fusion mRNA: Renilla luciferase - 1st segment of Fra-1 3’UTR 
psiCHECK-2-Fra-1 seg 2 Fusion mRNA: Renilla luciferase - 2nd segment of Fra-1 3’UTR 
psiCHECK-2-Fra-1 seg 3 Fusion mRNA: Renilla luciferase - 3rd segment of Fra-1 3’UTR 
The plasmid maps are displayed in chapter 3.4.11.2. 
 
 
2.6. Enzymes 
AccuPrime Pfx DNA Polymerase, 2.5 U/µl Invitrogen, Karlsruhe 
CIAP, 1 U/µl MBI Fermentas, Vilnius, Lithuania 
NotI, 10 U/µl New England Biolabs, Schwalbach 
Pfu DNA Polymerase recombinant, 2.5 U/µl MBI Fermentas, Vilnius, Lithuania 
Platinum Taq DNA Polymerase, 5 U/µl Invitrogen, Karlsruhe 
PmeI, 5 U/µl MBI Fermentas, Vilnius, Lithuania 
PRECISOR High-Fidelity DNA Polymerase, 2 U/µl BioCat, Heidelberg 
RNaseH, 5 U/µl New England Biolabs, Schwalbach 
SuperScript™ II Reverse Transcriptase, 200 U/µl Invitrogen, Karlsruhe 
SuperScript™ III Reverse Transcriptase, 200 U/µl Invitrogen, Karlsruhe 
T4 Polynucleotide Kinase, 10,000 U/ml New England Biolabs, Schwalbach 
T4 DNA Ligase, 400 U/µl New England Biolabs, Schwalbach 
XhoI, 20 U/µl New England Biolabs, Schwalbach 
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2.7. Size Markers 
BenchMark™ Prestained Protein Ladder   Invitrogen, Karlsruhe 
GeneRuler™ DNA Ladder Mix    MBI Fermentas, Vilnius, Lithuania 
PageRuler™ Plus Prestained Protein Ladder  MBI Fermentas, Vilnius, Lithuania 
 
 
2.8. Kits 
Dual-Luciferase® Reporter Assay System   Promega, Mannheim 
Effectene® Transfection Reagent    Qiagen, Hilden 
HiPerFect Transfection Reagent    Qiagen, Hilden 
LightCycler® FastStart DNA MasterPLUS SYBR Green I Roche, Mannheim 
Lipofectamine™ 2000     Invitrogen, Karlsruhe 
MinElute Gel Extraction Kit     Qiagen, Hilden 
miRNeasy Kit       Qiagen, Hilden 
One Shot® TOP10 competent cells    Invitrogen, Karlsruhe 
QIAquick Gel Extraction Kit     Qiagen, Hilden 
Qiagen® Plasmid Purification Maxi Kit   Qiagen, Hilden 
QIAprep® Miniprep Kit     Qiagen, Hilden 
RNeasy® Kit       Qiagen, Hilden 
Zero Blunt® Topo® PCR Cloning Kit   Invitrogen, Karlsruhe 
 
 
2.9. Antibodies 
Antibody Manufacturer Epitope Application 
Actin (Clone 4) 
mouse monoclonal IgG 
cat # 691001 
lot # 5029J 
MP Biomedical, 
Eschwege 
Chicken gizzard actin Western, 1:100,000 
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ATF2 (N-96) 
rabbit polyclonal IgG 
cat # sc-6233x 
lot # A2607 
Santa Cruz Bio-
technology, Santa 
Cruz 
Amino acids 1-96 of 
human ATF-2 
Western, 1:10,000 
Dicer [13D6] 
mouse monoclonal IgG 
cat # ab14601 
lot # 348991 
Abcam, Cam-
bridge (UK) 
N-terminus of human 
Dicer 
Western, 1:1,000 
Drosha 
rabbit polyclonal IgG 
cat # ab12286 
lot # 291586 
Abcam, Cam-
bridge (UK) 
Synthetic peptide de-
rived from within resi-
dues 1-100 of human 
Drosha 
Western, 1:400 
c-Fos 
rabbit polyclonal IgG 
cat # 06-341 
lot # 23255 
Upstate Cell Sig-
naling, Hamburg 
Amino acids 3-16 of 
human c-Fos 
Western, 1:10,000 
c-Fos 
rabbit polyclonal IgG 
cat # sc-52x 
lot # I0403 
lot # J1008 
Santa Cruz Bio-
technology, Santa 
Cruz 
N-terminus of human 
c-Fos 
EMSA, 2µg 
Fra-1 
rabbit polyclonal IgG 
cat # sc-605x 
lot # I0106 
Santa Cruz Bio-
technology, Santa 
Cruz 
N-terminus of Fra-1 of 
rat origin 
Western, 1:10,000 
EMSA, 2µg 
c-Jun 
rabbit polyclonal IgG 
cat # sc-1694 
lot # I3004 
Santa Cruz Bio-
technology, Santa 
Cruz 
Amino acids 1-79 
mapping at the N-
terminus of human c-
Jun p39 
Western, 1:500 
p-c-Jun 
mouse monoclonal IgG1 
cat # sc-822x 
lot # E0704 
Santa Cruz Bio-
technology, Santa 
Cruz 
Amino acids 56-69 of 
human c-Jun 
EMSA, 2µg 
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Anti-rabbit IgG HRP 
cat # W401B 
lot # 21357802 
Promega, Mann-
heim 
Secondary antibody, 
HRP conjugated 
Western, 1:10,000 
Anti-mouse IgG HRP 
cat # W402B 
lot # 2157906 
Promega, Mann-
heim 
Secondary antibody, 
HRP conjugated 
Western, 1:10,000 
All antibodies being used for Western blot analysis were diluted with blocking buffer. 
 
 
2.10. Consumables 
Cell culture flaks    (Corning) Sigma-Aldrich, Munich 
Cell culture plates    Greiner Bio-One, Frickenhausen 
Cell scraper     Carl Roth GmbH & Co, Karlsruhe 
Cryotubes     Greiner Bio-One, Frickenhausen 
Cristal pipette tips    Greiner Bio-One, Frickenhausen 
Eppendorf tubes    Eppendorf, Hamburg 
Films Hyperfilm ECL    Amersham Bioscience, Freiburg 
Graduated pipettes    Hirschmann, Eberstadt 
Hybond-N+ Nylon membrane  Amersham Bioscience, Freiburg 
MicroSpin™ G-25 Columns   GE Healthcare, Buckinghamshire 
Pipette tips     Eppendorf, Hamburg 
Photometer plastic cuvettes   Greiner Bio-One, Frickenhausen 
Polypropylene conical tubes   (Falcon) BD, Heidelberg 
Protrans membrane    Schleicher & Schüll, Dassel 
PVDF membrane (Immobilon P)  Millipore, Eschborn 
15% Polyacrylamide / TBE-Urea gel  Bio-Rad, Hercules, CA (USA) 
Saran wrap     Toppits, Minden 
Scalpels, disposable    Feather Safety Razor Company, Osaka (JP) 
Sterile needles, Microlancer™ 3  Becton Dickinson, Heidelberg 
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Sterile filters MILLEX®-GS 0.22µm  Millipore, Molsheim (F) 
TipOne Pipette Filter Tips   Starlab, Ahrensburg 
Whatman 3MM filter paper   Schleicher & Schüll, Dassel 
X-ray films, Super RX   Fuji, Tokyo (JP) 
 
 
2.11. Apparatuses & laboratory equipment 
Agilent 2100 Bioanalyzer   Agilent Technologies, Waldbronn 
Analytical Scale AE 160   Mettler, Gießen 
Analytical Scale basic   Sartorius, Göttingen 
Autoradiography cassettes   Kodak, Stuttgart 
Bacteria shaker G25    Infors, Bottmingen (CH) 
Bioruptor     Diagenode, Liège (B) 
BioPhotometer    Eppendorf, Hamburg 
Camera, UV light    Renner, Dannstadt 
Centrifuge Biofuge, Varifuge RF  Heraeus, Hanau 
Centrifuge 5415 R    Eppendorf, Hamburg 
Centrifuge MIKRO 120   Hettich, Tuttlingen 
Developer machine Curix 60   AGFA, Cologne 
DNA Engine DYAD and Tetrad 2 Cycler Bio-Rad Laboratories, Munich 
Geiger counter LB 1210B   Berthold, Wildbad 
Gel drier 483     Bio-Rad Laboratories, Munich 
Hybridization oven /shaker   Bibby Scientific Ltd, Stone (UK) 
Lab Dancer Mini Vortexer   VWR, Lutterworth (UK) 
LightCycler 1.5    Roche, Mannheim 
Microscope CKX41SF   Olympus Corporation, Tokyo (JP) 
Minifuge     Heraeus, Hanau 
Mini-PROTEAN II™    Bio-Rad Laboratories, Munich 
NanoDrop® ND-1000   NanoDrop Technologies, Wilmington (USA) 
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Neubauer counting chamber   Bender & Hobein, Bruchsal 
PCR ThermoCycler MultiCycler PTC2000 Bio-Rad Laboratories, Munich 
pH-meter Calimatic 765   Knick, Egelsbach 
Photometer Ultraspec 3000   Amersham Bioscience, Freiburg 
BioPhotometer     Eppendorf, Hamburg 
Plate reader Mithras LB 940   Berthold Technologies, Bad Wildbad 
Pipetboy acu     Hirschmann, Eberstadt 
Pipettes 2.5µl, 10µl, 20µl, 200µl, 1000µl Eppendorf, Hamburg 
Power Supply PHERO-stab 500  Biotech-Fischer, Reiskirchen 
Shaker Polymax 2040   Heidolph Instruments, Schwabach 
Scale 1216 MP    Sartorius, Göttingen 
Software MikroWin 2000   Mikrotek Laborsysteme, Overath 
Sonifier 250     Branson/Heinemann, Schwäbisch Gmünd 
SterilGARD Hood    Baker Company, Sanford, Maine (USA) 
STERI-CULT 200 Incubator   Forma Scientifc, Marietta, Ohio (USA) 
Thermomixer compact   Eppendorf, Hamburg 
UV Stratalinker® 1800   Stratagene, La Jolla, CA (USA) 
Water bath     Julabo, Seelbach 
Blotting chamber, semi-dry   Hoefer Pharmacia Biotech, San Francisco, CA
      (USA) 
 
 
2.12. Cell lines 
Cell line Characteristics Reference 
HeLa Species: human, female, adult 
Tissue: Cervix, adenocarcinom 
Viral status: HPV18-positive 
In vivo phenotype: tumorigenic after s.c. injection into 
nu-/- mice 
(Boshart et al., 1984) 
(Schwarz et al., 1985) 
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caryotype: aneuploid 
444 HeLa x fibroblast hybrids 
Viral status: HPV18-positive 
In vivo phenotype: non-tumorigenic after s.c. injection 
into nu-/- mice 
caryotype: tetraploid 
(Stanbridge, 1984) 
CGL3 HeLa x fibroblast hybrids (segregant of 444) 
Viral status: HPV18-positive 
In vivo phenotype: tumorigenic after s.c. injection into 
nu-/- mice 
caryotype: tetraploid 
(Stanbridge, 1984) 
 
 
2.13. Solutions and buffers 
All buffers were prepared with bidistilled water, if not mentioned otherwise. 
Ampicillin 50mg/ml 
Aliquoted, storage at -20°C 
APS 10% (w/v) 
Aliquoted, storage at -20°C 
Blocking buffer (Western blot) 1xTBS, pH 7.6 
0.1% (v/v) Tween 20 
5% (w/v) Milk powder 
Storage at 4°C 
BSA (protein quantification) 1µg/µl 
Aliquoted, storage at -20°C 
BSA (EMSA binding buffer 5x) 60mg/ml 
Storage at -20°C 
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Buffer A 10mM HEPES, pH 7.9 
10mM KCl 
0.1mM EDTA, pH 8.0 
0.1mM EGTA, pH 7.9 
Storage at -20°C 
Addition of protease and phosphatase inhibi-
tors prior to use (see 3.2.1) 
Buffer C 20mM HEPES, pH 7.9 
400mM NaCl 
1mM EDTA, pH 8.0 
1mM EGTA, pH 7.9 
25% Glycerin 
Storage at -20°C 
Addition of protease and phosphatase inhibi-
tors prior to use (see 3.2.1) 
CIA 49 parts Chloroform 
1 part Isoamyl alcohol 
Storage light protected at 4°C 
DEPC water 0.1% (v/v) DEPC 
Incubation overnight, then autoclavation 
DMEM, complete 500ml DMEM 
50ml FBS 
100U/ml Penicillin 
100µg/ml Streptomycin 
Storage at 4°C 
DMEM, freezing medium 60% (v/v) DMEM complete 
30% FBS 
10% DMSO 
sterile filtered through 0.22µm filter 
DNA lysis buffer (3x) 1.5% (w/v) SDS 
150mM Tris, pH 7.8 
150mM EDTA, pH 8.0 
DTT 0.1M 
Aliquoted, storage at -20°C 
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EDTA 0.5M, pH 8.0 
Adjust pH with NaOH conc. 
EGTA 0.25M, pH 7.9 
EMSA binding buffer (5x) 50% (v/v) Glycerin 
60mM HEPES, pH 7.9 
20mM TRIS, pH 8.0 
300mM KCl 
5mM EDTA, pH 8.0 
3µg/µl BSA 
Addition of protease and phosphatase inhibi-
tors prior to use (see 3.2.5) 
E-64 2.5mg/ml in 50% ethanol 
Aliquoted, storage at -20°C 
Freezing medium 10% (v/v) DMSO 
30% (v/v) FBS 
60% (v/v) DMEM 
Storage at -20°C 
Kanamycin 30mg/ml 
Aliquoted, storage at -20°C 
Laemmli buffer (10x) 0.25M TRIS 
1.9M Glycine 
1% (w/v) SDS 
LB-Medium 10g NaCl 
10g Bacto Krypton 
5g yeast extract 
ad 1000ml 
Adjust to pH 7.2 
LB-ampicillin agar plates 2% Bacto-Agar in LB-medium 
50µg/ml Ampicillin 
LB-kanamycin agar plates 2% Bacto-Agar in LB-medium 
30µg/ml Kanamycin 
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MOPS buffer (20x) 400mM MOPS 
100mM NaAc 
20mM EDTA 
DEPC water 
Adjust to pH 7.0 
Storage light protected 
Pefabloc SC 23.8mg/ml 
Aliquoted, storage at -20°C 
PMSF 0.01mg/ml in isopropanol 
Storage at -20°C 
Poly(dI/dC).poly(dI/dC) 1mg/ml (10U=500µg) in TNE 
Annealing: 10min at 45°C, cooling to 20°C 
Aliquoted, storage at -20°C 
Ripa (1x) 10mM TRIS, pH 8.0 
150mM NaCl 
1mM EDTA, pH 8.0 
1% NP-40 
0.1% SDS 
RNA loading buffer (2x) 50% Formamide 
2.2M Formaldhyde 
1% (w/v) Ficoll 400 
0.02% (w/v) Bromophenol blue 
1x MOPS buffer 
DEPC water 
Storage at -20°C 
RNA loading buffer (3x) (miRNA Northern blot) 8M Urea 
1x TBE 
30mM EDTA 
20% (v/v) Glycerin 
0.03% (w/v) Bromophenol blue 
0.03% (w/v) Xylencyanol 
DEPC water 
Storage at -20°C 
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RNase A 10mg/ml RNase A 
10mM Tris, pH 7.5 
15mM NaCl 
80°C, 20min 
Storage at -20°C 
SDS 10% (w/v) 
SDS loading buffer (5x) 10% (w/v) SDS 
0.03% (w/v) Bromophenol blue 
12.5% (v/v) 2-Mercaptoethanol 
5mM EDTA, pH 8.0 
50% (v/v) Glycerin 
300mM TRIS, pH 6.8 
Aliquoted, storage at -20°C 
SOC medium 2% (w/v) Bacto-Trypton 
0.5% (w/v) yeast extract 
10mM NaCl 
2.5mM KCl 
10mM MgCl2 
10mM MgSO4 
20mM glucose 
Sodium fluoride 500mM NaF 
Aliquoted, storage at -20°C 
Sodium ortho-vanadate 10mM Na3VO4 
Adjust to pH 10.0 
Aliquoted, storage at -20°C 
SSC (20x) 3M NaCl 
0.3M Na3Citrate 
pH 7.0 
Stripping solution (miRNA Northern blot) 0.5% SDS (w/v) 
DEPC water 
TAE (50x) 2M TRIS 
0.25M NaAc 
0.05M EDTA, pH 8.0 
Adjust to pH 7.8 with acetic acid 
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TBE (10x) 0.9M TRIS 
0.9M Boric acid 
0.02M EDTA, pH 8.0 
TBS (10x) 100mM TRIS 
1.37M NaCl 
Adjust to pH 7.6 
TBST (1x) 1xTBS pH 7.6 
0.1% (v/v) Tween 20 
TE (1x) 10mM TRIS 
1mM EDTA, pH 8.0 
TNE (1x) 1x TE, pH 8.0 
100mM NaCl 
Adjust to pH 7.4 with NaOH conc. 
Towbin (10x) 250mM TRIS 
1.92M Glycine 
Add 10% (v/v) Methanol prior to use 
Transfer buffer (miRNA Northern blot) 1xTBE 
DEPC water 
Trypan blue 0.25% (w/v) in 1xPBS 
Wash solution 1 (miRNA Northern blot) 2xSSC 
0.05% SDS 
EPC water 
Wash solution 2 (miRNA Northern blot) 0.1xSSC 
0.1% SDS 
DEPC water 
 
 
2.14. Search engines 
Search engine Internet address Reference 
TargetScan 
Release: 5.1 (04/2009) 
http://www.targetscan.org/ (Lewis et al., 2005) 
(Grimson et al., 2007) 
(Friedman et al., 2009) 
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PicTar 
Release: 03/26/2007 
http://pictar.mdc-berlin.de/ (Krek et al., 2005) 
(Lall et al., 2006) 
miRBase 
Release: 5 (11/2007) 
http://microrna.sanger.ac.uk/targets/v5/ (Enright et al., 2003) 
(Griffiths-Jones et al., 
2006) 
(Griffiths-Jones et al., 
2008) 
DIANA-microT 
Release: 3.0 (04/2009) 
http://diana.cslab.ece.ntua.gr/microT/ (Maragkakis et al., 2009) 
 
 
 
 
3. Methods  49 
3. Methods 
3.1. Cultivation of eukaryotic cells 
3.1.1. Cell culture 
Cells were cultured in complete DMEM. When reaching 80-90% confluence, they were 
split by washing once with 1xPBS and trypsinizing at 37°C for 5min. Then, Trypsin was inacti-
vated with fresh media and cells were plated again at various dilutions ranging from 1:5 to 
1:30, depending on scheduled experiments. All media were prewarmed at 20°C. 
 
 
3.1.2. Cryoconservation and reactivation of eukaryotic cells 
Cells were trypsinized as described in 3.1.1 and resuspended in complete DMEM. 
Then, cells were centrifuged at 800rpm for 5min. DMEM complete was replaced by freezing 
medium, precooled to 4°C. Afterwards, cell suspensi ons were aliquoted into cryotubes, which 
were rolled into a thick pile of paper towels and subsequently stored at -80°C. After two 
weeks, cryotubes were transferred into the cell tank for long-term conservation at -196°C. 
When fresh cells were needed, a cryotube was slowly thawed on ice and the cell sus-
pension was transferred into a falcon tube with 5ml complete DMEM, prewarmed at 25°C. Af-
ter washing, cells were resuspended with complete DMEM and plated into a cell culture dish. 
After 2-3 passages cell were used for experiments. 
 
 
3.1.3. Cell counting 
100µl of a cell suspension in complete DMEM were mixed with 100µl Trypan blue solu-
tion and loaded onto the Neubauer chamber. All four quadrants (each comprising 16 fields) 
were counted and numbers were added up. The final cell concentration [cells/ml] was calcu-
lated as described by the formula: 
cell number
2 10
4
= 
cells
ml
.
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3.2. Preparation and analysis of proteins 
3.2.1. Nuclear protein preparation (Schreiber et al., 1989) 
Nuclear protein extracts were prepared applying the method from Schreiber et al., 
1989. Furthermore, phosphatase and protease inhibitors were added to buffers A and C at 
concentrations according to the manufacturers’ suggestions. 
60cm2 cell culture plates with 90-100% confluent cells were washed twice with isotonic 
1xPBS. Then, 1.2ml buffer A were added, cells were scraped from the plates, transferred into 
Eppendorf tubes and incubated for 15min to allow hypotonic swelling of the cells. Subse-
quently, 75µl non-ionic detergent Nonidet® P40 (10% aqueous solution) were added (final 
concentration 0.59%) and cell suspensions were vortexed 10sec to lyse the plasma mem-
branes. After centrifugation at 13,000rpm, 1min, intact nuclei were separated from the super-
natants containing cytoplasmic proteins and RNA. 
Supernatants were subsequently used for RNA preparation (see 3.3.1). 
Pellets were resuspended in 100µl high-salt buffer C and incubated for 30min while 
tubes were shaken every 5min. Finally, extracts were centrifuged at 13,000rpm, 5min, and the 
clarified supernatants containing nuclear proteins were transferred into fresh Eppendorf tubes 
and stored at -80°C. All steps, buffers and centrif ugations were done and applied at 4°C. 
Protein concentrations were determined with the Bradford assay (see 3.2.3). 
 
Inhibitor Function Stock solution Final concentration 
DTT Reducing agent 0.1 M 1 mM 
E-64 Cysteinprotease inhibitor 2.5 µg/ml 5 µg/ml 
NaF Phosphatase inhibitor 0.5 M 1 mM 
Na3VO4 Phosphatase inhibitor 10 mM 0.2 mM 
Pefabloc SC Serinprotease inhibitor 23.8 mg/ml 0.5 mg/ml 
Table 3-1: Additives for buffers A and C 
 
 
3.2.2. Whole cell protein preparation (RIPA) (Klotz et al., 1999) 
Whole cell protein extracts were prepared with chilled Ripa buffer supplemented with 
PMSF. 20cm2 cell culture plates with 90-100% confluent cells were washed twice with isotonic 
1xPBS. Then, 400µl Ripa buffer were added, cells were scraped from the plates and trans-
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ferred into Eppendorf tubes. To lyse cell membranes, cell suspensions were sonified twice, 
10sec, with Sonifier 250 set to: timer “hold”, duty cycle “50%” and output control “5”. Subse-
quently, suspensions were incubated at 4°C, 30min t o allow complete protein extraction. After 
vortexing 2sec and centrifugation at 13,000rpm, 5min, supernatants, containing whole cell 
proteins, were transferred into fresh tubes and stored at -80°C. All work was done on ice at 
4°C. 
Protein concentration was determined with the Bradford assay (see 3.2.3). 
 
Inhibitor Function Stock solution Final concentration 
PMSF Serinprotease inhibitor 10 mg/l (isopropanol) 0.1 µg/ml 
Table 3-2: Additive for RIPA buffer 
 
 
3.2.3. Protein quantification according to Bradford (Bradford, 1976) 
All protein extracts were quantified with the colorimetric Bradford assay basing on the 
dye Coomassie Brilliant Blue G-250. The read-out depends upon the change of absorbance at 
a wave-length of 595nm when G-250 binds to proteins containing arginine and aromatic 
amino acids. The assay was carried out as follows: 800µl of bidistilled water were mixed with 
200µl Bradford reagent and 1-10µg BSA to generate a straight calibration line or 2µl of protein 
extracts. Solutions were vortexed 2sec and measured with a spectrophotometer, calibrated 
with water and Bradford reagent. Protein concentrations were calculated with their repective 
extinction values using the straight calibration line. 
 
 
3.2.4. Western blot analysis 
3.2.4.1. SDS-polyacrylamide gel electrophoresis 
(Laemmli, 1970; Hames and Rickwood, 1990) 
With SDS-polyacrylamide-gel electrophoresis (SDS-PAGE), proteins were separated 
according to their size. This system is based on a discontinuous SDS-polyacrylamide-gel with 
a low-percentage stacking gel and a high-percentage running gel. The stacking gel concen-
trates the samples whereas they are separated in the running gel. Negatively charged SDS in 
loading buffer and gels attaches to hydrophobic regions of proteins in a constant weight ratio, 
thereby over-neutralizing positive charges, denaturing and solubilizing proteins. The scaffold 
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of the gels, the polyacrylamide, serves as a molecular filter separating proteins only according 
to their size, while they are migrating towards the anode. Resolution depends on the concen-
tration of polyacrylamide. For an optimal separation, 10% running gels for proteins of 40-
70kDa and 6% running gels for bigger proteins were used. 
 
 Stacking gel Running gel, 6% Running gel, 10% 
Tris, pH 6.8 0.126M ----- ----- 
Tris, pH 8.8 ----- 0.376M 0.376M 
SDS 0.1% (w/v) 0.1% (w/v) 0.1% (w/v) 
Acrylamide/bis-
Acrylamide (29:1) 
3% (w/v) 6% (w/v) 10% (w/v) 
APS 0.05% (w/v) 0.05% (w/v) 0.05% (w/v) 
TEMED 0.12% (v/v) 0.06% (v/v) 0.06% (v/v) 
Table 3-3: Composition of stacking and running gels 
 
For analysis, 12-15µg of nuclear or whole cell protein extracts were mixed with SDS 
loading buffer (1x final concentration) and incubated at 99°C, 3min. Immediately afterwards, 
samples were cooled on ice for 5min, centrifuged and loaded onto the wells. In order to de-
termine the size of the proteins of interest, a prestained protein ladder was used as a size 
marker. Gels were first run at 15mA/gel and then at 30mA/gel when proteins reached the run-
ning gel. Electrophoresis was stopped when bromophenol blue exited the gel. 
 
 
3.2.4.2. Western-blot transfer (Gallagher et al., 1997) 
Proteins separated by SDS-PAGE (see 3.2.4.1) were subsequently transferred with 
the “semi-dry” method onto a Polyvinylidendifluorid-membrane (PVDF) (Towbin et al., 1979; 
Gallagher et al., 1997). After gel-electrophoresis, the gel was placed on top of the membrane 
that had been hydrated with methanol for 1min, washed with bidistilled water for 5min and 
then placed in Towbin buffer for 15min. The top and the bottom of the pile was composed of 
Whatmann 3MM filter paper that had been placed in Towbin buffer to serve as a reservoir for 
ions. Membrane and filter papers matched the size of the polyacrylamide gel. The assembly 
looked as follows from top to bottom: cathode – 8 sheets of filter paper – gel – membrane – 8 
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sheets of filter paper – anode. The transfer was conducted at 4°C, with 1.2mA/cm 2/gel for 
70min. 
 
 
3.2.4.3. Immuno-detection and “enhanced chemiluminescence” (ECL) 
In the last step, proteins were detected indirectly with a specific, first antibody against 
the protein of interest and a secondary antibody raised against the species of origin of the first 
antibody (Schneppenheim et al., 1991). The secondary antibody was conjugated with horse-
radish peroxidase (HRP) that oxidized in the presence of hydrogen peroxide luminol to a di-
oxetan compound. The product was unstable and decomposed while emitting light. Finally, 
this light was detected as “enhanced chemiluminescence” via autoradiography. 
In order to inhibit unspecific binding, the membrane was blocked in blocking solution 
for at least 1h at 20°C. Then, the membrane was inc ubated with the first antibody in the re-
spective dilution on a shaker at 4°C overnight. Nex t day (all steps were carried out at 20°C), 
the membrane was washed with TBST, 30min, incubated with the secondary antibody for 1h 
and subsequently washed again with TBST, 30min. Finally, the membrane was incubated for 
1min with the ECL reagent and proteins were detected via autoradiography by exposing to X-
ray films for seconds to minutes depending on the intensity of the signal. 
 
 
3.2.4.4. Stripping of PVDF membranes 
In order to detect different proteins on the same membrane, the previous protein-
specific, first antibody was removed as follows (each step lasting 5min): washing with TBST 
and bidistilled water, stripping with 0.2 M NaOH to remove the old antibody while keeping the 
epitopes of the proteins for new antibody binding, and subsequently washing with bidistilled 
water and TBST. Finally, the membrane was blocked again with blocking buffer for 1h. Then, 
the membrane was ready to be reincubated with another antibody as described in 3.2.4.3. 
 
 
3.2.5. Electrophoresis mobility shift assay (EMSA) 
The electrophoresis mobility shift assay (EMSA) determines the interaction between 
DNA and DNA-binding proteins, such as the interaction of transcription factors with their cor-
responding regulatory regions. The electrophoresis mobility shift assay, also known as gel re-
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tention assay, bases on different migration abilities through a non-denaturizing polyacrylamide 
gel of protein-DNA complexes and DNA alone. Protein-DNA complexes migrate more slowly 
due to their increased size than unbound, double-stranded oligonucleotides. By adding spe-
cific antibodies to the reaction prior to the gel run, complexes are further increased in size and 
thus further retarded, allowing identification of the bound proteins. The employed oligonucleo-
tides were made with an Applied Biosystems synthesizer using phosphoramitide chemistry 
and subsequent HPLC purification. 
Oligonucleotide strands (sense and antisense) were annealed in TNE in a PCR ma-
chine applying the following program: 85°C for 10mi n followed by a temperature decrease of 
0.5°C every 30sec. 200ng of annealed oligonucleotid es were end-labeled with 3,000Ci/mmol 
[γ-32P] dATP and T4 polynucleotide kinase at 37°C for 30 min. Non-incorporated oligonucleo-
tides were removed by gel-purification: 15% polyacrylamide/1xTBE-gel electrophoresis at 
200V for 90min. Subsequently, the radioactively labeled oligonucleotide was excised from the 
gel and extracted in TNE by shaking overnight at 4°C. 
The binding assay was performed in a 20µl reaction volume containing 1xEMSA bind-
ing buffer, 2µg poly(dI/dC).poly(dI/dC), 2µg nuclear protein extract and additives (Pefabloc 
SC2,5mg/ml, E-64 25µg/ml, NaF 5mM, DTT 5mM, Na3VO4 1mM). The mixture was incubated 
at 20°C, 5min. Then, 10,000cpm of 5’ end labeled, d ouble-stranded oligonucleotide probe 
were added and incubated for 30min at 20°C. Afterwa rds, for supershift analysis, 2µg of the 
specific antibody were added and the mixture was additionally incubated at 4°C, 1h. Finally, 
protein-DNA complexes were resolved in a 5.5% non-denaturizing polyacrylamide/1xTBE-gel 
which was subsequently dried on a Whatmann 3MM filter paper and exposed to X-ray films at 
-80°C for hours to days depending on the intensity of the signal. 
 
 
3.3. Preparation and analysis of nucleic acids 
3.3.1. Genomic DNA preparation 
Cells were washed twice with 1xPBS, incubated with 3ml DNA lysis buffer for 10min at 
20°C, scrapped and transferred into 15ml falcon tub es. Proteinase K was added (200ng/µl fi-
nal concentration) and the mixture was incubated at 56°C for 1 hr. Nucleic acids were purified 
using phenol/chloroform extraction. After centrifugation, the upper, DNA-containing, aqueous 
phase was transferred into a new tube where DNA was precipitated after addition of ammo-
nium acetate (2M final concentration) and 0.8 volumes of isopropanol. The mixture was centri-
fuged and the pellet was washed twice with 70% ethanol, air-dried and resuspended in TE 
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buffer. Finally, gDNA was treated with RNAse A (Ribonuclease A, 10µg/ml) 10 minutes at 
37°C. gDNA was stored at 4°C. 
 
 
3.3.2. Cytoplasmic RNA preparation 
Cytoplasmic RNA was isolated from buffer A extracts after separation from the nuclei 
(see 3.2.1) with the RNeasy Kit according to the manufacturer’s instructions. 1 volume super-
natant was mixed with 2 volumes RLT buffer containing 1% β-mercaptoethanol and 1.5 vol-
umes EtOH, loaded stepwise onto a column and centrifuged at 10,000rpm, 15sec. For wash-
ing, the column was centrifuged once with 700µl RW1 buffer and twice with 500µl RPE buffer. 
Afterwards, the column was dried by centrifuging at 10,000rpm, 15sec. Finally, RNA was 
eluted with 30µl RNase-free water and stored at -80°C. 
 
 
3.3.3. Total RNA preparation 
Total RNA including miRNAs was isolated with the miRNeasy Kit according to the 
manufacturer’s instructions. 3x106 “444” and 5x106 “CGL3” and HeLa cells were seeded in 
60cm2 cell culture plates and grown until 90-100% confluence was reached: “444” cells after 
1d, “CGL3” and HeLa cells after 2d. First, cells were washed twice with ice-cold 1xPBS and 
scrapped off the plates in 1ml 1xPBS. Cell suspension was transferred into an Eppendorf tube 
which was centrifuged at 2,000rpm, 2min, to replace the 1xPBS with 700µl QIAzol. The sus-
pension was vortexed until all cells were dissolved and then the solution was incubated at 
20°C, 5min. Afterwards, 140µl Chloroform were added , the mixture was vigorously shaken for 
15sec and incubated for 3min. The dispersion was transferred into a fresh tube and centri-
fuged at 13,000rpm for 15min at 4°C. The upper, aqu eous phase was transferred into a new 
tube (~350µl) and 1.5 volumes EtOH (~525µl) were added. After vortexing, the solution was 
loaded stepwise onto a column and centrifuged at 10,000rpm, 15sec. For washing, the col-
umn was centrifuged once with 700µl RWT buffer and twice with 500µl RPE buffer. After-
wards, the column was dried by centrifuging twice at 10,000rpm, 2min. Finally, total RNA was 
eluted with 30µl RNase-free water and stored at -80°C. 
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3.3.4. Nucleic acid quantification 
RNA, prepared according to 3.3.2 or 3.3.3, plasmid DNA (see 3.4.11) and genomic 
DNA (see 3.3.1) were quantified using the Nanodrop® ND-1000 Spectrophotometer according 
to the manufacturer’s instructions. Absorbances at 230nm, 260nm and 280nm were meas-
ured. Sample concentrations were automatically calculated according to the Beer-Lambert 
equation: 
 
c = (A * e)/b  c = concentration [ng/µl] 
   A = absorbance at 260nm [AU] 
   e = wavelength-dependent extinction coefficient [ng*cm/µl] 
    dsDNA: 50 
    ssDNA: 33 
    RNA:  40 
   b = path length [cm] 
 
To determine nucleic acid purity the quotient 260nm/230nm, which should be 1.8-2.2, and the 
quotient 260nm/280nm, which should be ~2.0, were calculated. 
 
 
3.3.5. RNA agarose gel electrophoresis 
RNA that had been prepared according to 3.3.2 or 3.3.3 was separated in 1% agarose 
/ 1xMOPS / ethidium bromide gels under non-denaturing conditions. 1µg RNA were incubated 
with RNA-loading buffer at 65°C for 10min and coole d down to 4°C for 3min prior to loading. 
Gels were run at 100V and bands were visualized with UV-light. Equal intensities of ribosomal 
RNAs indicated correct quantifications (see 3.3.4) and RNA quality was assessed by the ab-
sence of degradation products of the ribosomal RNAs 28S and 18S. 
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3.3.6. Reverse transcription 
3.3.6.1. Reverse transcription with SuperScript™ II 
1-2µg cytoplasmic RNA (see 3.3.2) were used with 200ng random primers for all 
cDNAs analyzed in quantitative RT-PCRs (see 3.3.8). 2µg total RNA were used with 0.05nmol 
oligo d(T)23 primer for cloning purposes (see 3.4). 2µg total RNA (see 3.3.3) were used for 
semi-quantitative RT-PCR analysis of pri-/pre-miRNAs (see 3.3.7.2). 
According to the manufacturer’s instructions, RNA was incubated with random primers 
or oligo d(T)23 at 70°C for 10min and cooled down on ice. Then, th e mixture was supple-
mented with 1x First-Strand Buffer (50mM Tris-HCl, 75mM KCl, 3mM MgCl2), 10mM DTT and 
0.5mM dNTPs and incubated at 25°C for 10min. After annealing of the primers, 100U Super-
Script™ II was added and the reaction was incubated at 42°C for 50min, then heated up to 
70°C for 15min and finally cooled down to 4°C. cDNA  was stored at -20°C. 
 
 
3.3.6.2. Reverse transcription with SuperScript™ III 
According to the manufacturer’s instructions SuperScript™ III was used to clone the 
3’UTR of Dicer. 3µg cytoplasmic RNA (see 3.3.1) were incubated with 0.05nmol oligo d(T)23 
primers and 0.5mM dNTPs at 70°C for 10min and subse quently cooled down to 4°C. Then, 1x 
First-Strand Buffer, 10mM DTT and 400U SuperScript™ III were added and the mixture was 
incubated at 55°C for 60min, at 70°C for 15min and finally cooled down to 4°C. cDNA was 
stored at -20°C. 
 
 
3.3.7. Semi-quantitative polymerase chain reaction 
3.3.7.1. Primer test for qRT-PCR 
Semi-quantitative RT-PCR was used to test the specificity of primers that were used in 
quantitative RT-PCRs. cDNA was obtained with random primers and SuperScript™ II (see 
3.3.6.1). PCRs were performed in 25µl total volume with 2.5U Platinum Taq DNA Polymerase, 
1.5mM MgCl2, 0.8mM dNTPs, 1x PCR buffer (20mM Tris-HCl, 50mM KCl), 0.8µM primers and 
1µl cDNA. All PCR reactions were run with 35 cycles with a denaturation step at 94°C for 
30sec, an annealing step at primer-specific temperature for 45sec, an extension step at 72°C 
for 45sec and a final elongation step at 72°C for 1 0min. The PCR fragment was visualized in a 
2% agarose / ethidium bromide gel. 
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3.3.7.2. Analysis of pri-/pre-miRNA expression 
Semi-quantitative RT-PCR was also used to analyze the expression of pri-/pre-
miRNAs. cDNA was obtained with random primers and SuperScript™ II from total RNA (see 
3.3.6.1) that was, following reverse transcription, RNase H digested (see 3.4.2). PCRs were 
performed in 25µl total volume with 2.5U Platinum Taq DNA Polymerase, 1.5mM MgCl2, 
0.8mM dNTPs, 1x PCR buffer, 0.8µM primers and 0.5µl cDNA. All PCR reactions were run 
with 35 cycles with a denaturation step at 94°C for  30sec, an annealing step at primer-specific 
temperature for 45sec, an extension step at 72°C fo r 45sec and a final elongation step at 
72°C for 10min. The PCR fragment was visualized in a 4% agarose / ethidium bromide gel. 
 
 
3.3.8. Quantitative polymerase chain reaction 
The relative amount of cDNA of all analyzed genes was determined by quantitative 
RT-PCR using SYBR Green I according to the manufacturer’s instructions. SYBR Green I 
binds to dsDNA which results in a fluorescence dye absorbing blue light of 494nm and emit-
ting green light of 521nm. An increase in DNA product during PCR leads to a linear increase 
in fluorescence intensity, which is measured at the end of each cycle, therefore allowing DNA 
concentrations to be quantified. With reference to a standard dilution of 5 different amounts of 
pGAPDH (7.5ng, 750pg, 75pg, 7.5pg, 0.75pg), the cDNA concentrations of the genes of inter-
est could be determined. For correction of possible differences in RNA quantity and quality or 
inefficiency of the reverse transcription reaction, values of target genes were normalized 
against the internal reference gene GAPDH. The Ct-values (cycle threshold), which deter-
mines the cycle when the fluorescence intensity significantly rises for the first time above the 
background fluorescence, were then used for the calculations. 
Primers were tested according to 3.3.7 and cDNA was prepared with random primers 
and SuperScript™ II (see 3.3.6.1). For relative quantifications, a straight calibration line con-
sisting at least out of 3 of the 5 GAPDH values was generated. The values were chosen con-
sidering two criteria: inclusion of the cycle thresholds of the samples and a minimal error, usu-
ally 0.003 – 0.04. cDNA of target genes was relatively quantified by first subtracting the back-
ground (sample was water) and then by normalizing against GAPDH. Finally, values were 
displayed in Excel tables as percentages compared to control siRNA set to 100%. 
PCRs were performed in 10µl total volume with 1x SYBR Green (FastStart Taq DNA 
Polymerase, reaction buffer, MgCl2, SYBR Green I dye, dNTP mix), 2µM Primer and 1µl 
cDNA. PCRs were run following this program: 
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 Temp Hold Time Slope Acquisition Mode 
Denaturation 95°C 10min 20°C/sec None 
Amplification 95°C 10sec 20°C/sec None 
50 cycles Gene specific 5sec 20°C/sec None 
 72°C 20sec 20°C/sec Single 
Melting Curve 95°C 0sec 20°C/sec None 
 Gene specific -
10°C 
15sec 20°C/sec None 
 95 0 0.1°C/sec Continuous 
Cooling 40°C 30sec 20°C/sec None 
Table 3-4: qRT-PCR protocol 
 
 
3.3.9. Northern blot analysis 
Northern blotting was applied to control the down-regulation of miRNAs upon knock-
down of Drosha or Dicer. In principle, the technique is identical to Western blotting (see 3.2.4) 
where the focus is on proteins. Due to similarities, the techniques have been named according 
to the points of the compass after starting off with Southern blotting of DNA developed by 
Edwin Southern (Southern, 1975). First, RNA molecules are separated according to their size. 
Then, they are transferred onto a Nylon membrane, permanently fixed and autoradiographi-
cally detected. 
 
 
3.3.9.1. RNA PAGE electrophoresis 
Total RNA was obtained as described in 3.3.3, quantified (see 3.3.4) and quality-
checked (see 3.3.5). First, 10µg total RNA were filled up with Nuclease-free ddH2O to 10µl, 
mixed with 8µl RNA loading buffer (for miRNAs) and heated to 80°C for 10min and subse-
quently cooled down to 4°C. Then, samples were load ed onto a 15% Polyacrylamide / TBE-
Urea Ready gel (Bio-Rad) that had been prerun at 125V for 45min. The gel was run at 90V 
with 0.5xTBE until the bromophenol blue (~10nt) reached the end of the gel. Afterwards, to 
compare for equal loading, the ribosomal RNA bands were visualized with ethidium bromide. 
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3.3.9.2. Northern-blot transfer and crosslink 
RNAs, separated by PAGE electrophoresis (see 3.3.9.1), were subsequently trans-
ferred onto a membrane and cross-linked. After gel-electrophoresis, the gel was placed on top 
of the membrane that had been dampened with transfer buffer. Top and bottom of the pile 
were composed of Whatmann 3MM filter papers that had also been dampened with transfer 
buffer to serve as a reservoir for ions. Membrane and filter papers matched the size of the 
polyacrylamide gel. The assembly looked as follows from top to bottom: cathode – 9 sheets of 
filter paper – gel – membrane – 9 sheets of filter paper – anode. The transfer was conducted 
at 20°C, with 20V for 40min/gel. Afterwards, RNA wa s twice UV-cross-linked with the UV 
Stratalinker® set to “Autocrosslink” (120,000µJ). The filter was then stored at -80°C. 
 
 
3.3.9.3. Probe labeling 
Complementary ssDNA-oligonucleotides (Invitrogen) were used as probes against ma-
ture miRNAs. The kinase reaction was incubated for 60min at 37°C. Then, 30µl Nuclease-free 
ddH2O were added and the solution was transferred onto a MicroSpin™ G-25 Column. The 
column was centrifuged at 3,000rpm for 2min and the eluate, containing the radioactive-
labeled probe, was used immediately or stored at -20°C. 
 
 Final concentration Volume 
T4 Polynucleotide kinase [10U/µl] 0.5U/µl 1µl 
PNK buffer (10x) 1x 2µl 
ssDNA oligo [10µM] 1pmol/µl 2µl 
[γ-32P] dATP [10µCi/µl] 1µCi/µl 2µl 
Nuclease-free ddH2O ad 20µl 13µl 
Final volume  20µl 
Table 3-5: Kinase reaction 
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3.3.9.4. Hybridization, washing, detection 
Membranes were prehybridized in 5ml ExpressHyb™Hybridization Solution for 30min 
while rolling in the oven at 37°C. Then, membranes were hybridized for 60min and subse-
quently washed in the following order: 5min washing with wash solution 1, rolling in the oven, 
and 1min washing with wash solution 2, shaking on a rocking table. All wash solutions were at 
20°C. Finally, membranes were wrapped in saran wrap  and signals were detected by autora-
diography. Filters were exposed to an X-ray film at -80°C for hours to days which were subse-
quently processed in a developer machine. 
 
 
3.3.9.5. Stripping 
In order to hybridize membranes multiple times, the previous probe was removed by 
shaking the filters at 20°C with 100°C hot strippin g solution for 30min. This step was repeated 
until any radioactive signal was removed. 
 
 
3.4. Cloning techniques: preparation of reporter plasmids 
Full-length 3’UTRs of c-Jun, Fra-1, Net, Dicer and Oct-1 and segments of the 3’UTRs 
of c-Jun and Fra-1 were cloned behind the ORF of Renilla luciferase gene into the multiple 
cloning site of psiCHECK™-2. 
 
 
Figure 3-1: Vector map of psiCHECK™-2, © Promega 
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3.4.1. Cloning strategies 
The following cloning strategy (A) was applied to clone the 3’UTRs of c-Jun, Fra-1, 
Dicer, Oct-1 and the segments of c-Jun and Fra1. For Net 3’UTR the strategy was slightly 
modified (B). 
 
A B 
psiCHECK™-2 3‘UTR Inserts
Enzymatic digestion, 3.4.4.
Vector dephosphorylation, 3.4.6.
Gel purification / extraction, 3.4.5.1.
Vector purification, 3.4.5.2.
RNA preparation, 3.3.1.
Reverse transcription, 3.3.5.
RNase H digestion, 3.4.2.
PCR, 3.4.3.
Gel purification / extraction, 3.4.5.1.
Enzymatic digestion, 3.4.4.
Gel purification / extraction, 3.4.5.1.
Ligation with psiCHECK™-2, 3.4.7.
Transformation, 3.4.8.
Mini preparation, 3.4.9.
Control digestion, 3.4.4.
Sequencing, 3.4.10.
Maxi preparation, 3.4.11.
 
psiCHECK™-2 Net 3‘UTR insert
Enzymatic digestion, 3.4.4.
Vector dephosphorylation, 3.4.6.
Gel purification / extraction, 3.4.5.1.
Vector purification, 3.4.5.2.
RNA preparation, 3.3.1.
Reverse transcription, 3.3.5.
RNase H digestion, 3.4.2.
PCR, 3.4.3.
Ligation with Topo®, 3.4.5.1.
Gel purification / extraction, 3.4.5.1.
Ligation with psiCHECK™-2, 3.4.7.
Transformation, 3.4.8.
Control digestion, 3.4.4.
Maxi preparation, 3.4.11.
Transformation, 3.4.8.
Mini preparation, 3.4.9.
Control digestion, 3.4.4.
Sequencing, 3.4.10.
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Figure 3-2: Cloning strategies for different 3’UTRs 
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3.4.2. RNase H digestion 
cDNA that was used for cloning, was digested with RNase H to hydrolyze RNA which 
was hybridized to cDNA. cDNA was mixed with 10U RNase H and 1x RNase H buffer (50mM 
Tris-HCl, 75mM KCl, 3mM MgCl2, 10mM Dithiothreitol) and the mixture was incubated at 
37°C, 2h. Then, RNase H was heat-inactivated at 65° C, 20min. cDNA was stored at -20°C. 
 
 
3.4.3. Semi-quantitative PCR to amplify 3’UTRs for cloning 
Primers were chosen to harbor recognition sequences for SgfI, XhoI, PmeI and NotI – 
the restriction enzymes cutting in the multiple cloning site of psiCHECK™-2. All PCRs were 
run 5-8 folds in parallel to obtain enough amounts of fragments. 
 
Forward primer 
  
    overhang 
5’-         agg 
 
   SgfI 
gcgatcgc 
 XhoI 
ctcgag 
binding to cDNA 
xxxxxxxxxxxxxxx -3’ 
Reverse primer 
  
binding to cDNA 
3’- xxxxxxxxxxxxxxx 
   PmeI 
caaatttg 
 NotI 
cgccggcg 
overhang 
tgc           -5’ 
Table 3-6: Design of forward and reverse cloning primers 
 
3’UTRs of Fra-1 and Net were amplified using Pfu DNA Polymerase according to the 
manufacturer’s instructions. PCRs were performed in 25µl total volume with 1U Pfu DNA Po-
lymerase, 3mM MgSO4, 0.8mM dNTPs, 1x PCR reaction buffer (20mM Tris-HCl, 10mM 
(NH4)2SO4, 10mM KCl, 0.1% (v/v) TritonX-100, 0.1mg/ml BSA), 0.8µM primers and 1.5µl 
cDNA. All PCR reactions were run with 35 cycles with a denaturation step at 94°C for 30sec, 
an annealing step at 57°C for 45sec, an extension s tep at 72°C for 60sec and a final elonga-
tion step at 72°C for 10min. The PCR fragment was v isualized in a 1% agarose / ethidium 
bromide gel. 
The 3’UTR of c-Jun was amplified using AccuPrime Pfx DNA Polymerase according to 
the manufacturer’s instructions. The PCR was first run with primers without linkers. After ex-
traction of the band from the agarose gel (see 3.4.5.1), a nested PCR with primes harboring 
the linkers was prepared. PCRs were performed in 25µl total volume with 1.25U AccuPrime 
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Pfx DNA Polymerase, 1x PCR reaction buffer, 0.8µM primers and 1µl cDNA. All PCR reac-
tions were run with 35 cycles with a denaturation step at 94°C for 30sec, an annealing step at 
59°C for 45sec (or 57°C for nested PCR), an extensi on step at 68°C for 60sec and a final 
elongation step at 68°C for 10min. The PCR fragment  was visualized in a 1% agarose / 
ethidium bromide gel. 
The 3’UTR of Oct-1 was amplified using Platinum Taq DNA Polymerase according to 
the manufacturer’s instructions. The PCR was first run with primers without linkers. After ex-
traction of the band from the agarose gel (see 3.4.5.1), a nested PCR with primers harboring 
the linkers was prepared. PCRs were performed in 25µl total volume with 2.5U Platinum Taq 
DNA Polymerase, 1.5mM MgCl2, 0.8mM dNTPs, 1x PCR reaction buffer, 0.8µM primers and 
1µl cDNA. All PCR reactions were run with 35 cycles with a denaturation step at 94°C for 
30sec, an annealing step at 57°C for 45sec, an exte nsion step at 72°C for 45sec and a final 
elongation step at 72°C for 10min. The PCR fragment  was visualized in a 1% agarose / 
ethidium bromide gel. 
3’UTR of Dicer was amplified using Precisor High-Fidelity DNA Polymerase according 
to the manufacturer’s instructions. PCR was performed in 25µl total volume with 0.4U Precisor 
High-Fidelity DNA Polymerase, 1x GC PCR reaction buffer, 0.8µM primers, 0.8mM dNTPs 
and 0.75µl cDNA. PCR reaction was run with 35 cycles with a denaturation step at 97°C for 
30sec, an annealing step at 55°C for 45sec, an exte nsion step at 72°C for 5min and a final 
elongation step at 72°C for 10min. The PCR fragment  was visualized in a 1% agarose / 
ethidium bromide gel. 
3’UTR segments of c-Jun and Fra-1 were amplified using AccuPrime Pfx DNA Poly-
merase according to the manufacturer’s instructions. PCRs were performed in 25µl total vol-
ume with 1.25U AccuPrime Pfx DNA Polymerase, 1x PCR reaction buffer, 0.8µM primers, 2% 
DMSO and 10pg psiCHECK-2-c-Jun or psiCHECK-2-Fra-1, respectively. All PCR reactions 
were run with 35 cycles with a denaturation step at 94°C for 30sec, an annealing step at 55°C 
(c-Jun) or 59°C (Fra-1) for 45sec, an extension ste p at 68°C for 60sec and a final elongation 
step at 68°C for 10min. PCR fragments were visualiz ed in a 1% agarose / ethidium bromide 
gel. 
 
 
3.4.4. Analytical and preparative restriction enzyme digestion 
For analytical purposes, plasmids from mini preparations (see 3.4.9) were digested 
with restriction enzymes to identify positive clones with the respective insert. 500ng plasmid 
were digested in a mixture of 1x appropriate restriction buffer, 1x BSA and 10U of each re-
3. Methods  65 
striction enzyme at 37°C, 1h. The fragment pattern was visualized in a 1% agarose / ethidium 
bromide gel. Positive plasmids were sent to sequencing (see 3.4.10). 
For preparative purposes, psiCHECK™-2 and PCR products were digested with re-
striction enzymes to obtain compatible, sticky ends. PCRs were prepared (see 3.4.3) and 
PCR products were isolated from 1% agarose gels (see 3.4.5.1). Then, fragments or empty 
vector were digested in a mixture of 1x appropriate restriction buffer, 1x BSA and 10U of each 
restriction enzyme at 37°C, 1h. Afterwards, fragmen ts or vector were purified again with a 1% 
agarose / ethidium bromide gel (see 3.4.5.1). 
 
 
3.4.5. Purification of DNA 
3.4.5.1. Gel purification / extraction 
Fragments or vector were run in a 1-2% agarose / ethidium bromide gel to isolate 
them. Then, they were excised from the gel, extracted and purified by using the QIAquick Gel 
Extraction Kit according to the manufacturer’s instructions. The gel slice was first dissolved in 
QG buffer at 50°C. Then, isopropanol was added and the mixture was passed through the col-
umn by centrifuging at 10,000rpm for 1min. For washing, the column was centrifuged with 
500µl QG buffer and 750µl PE buffer and afterwards dried at 13,000rpm for 1min. Finally, 
DNA was eluted with 20-30µl EB buffer. DNA was stored at -20°C. 
 
 
3.4.5.2. MinElute Cleanup 
After dephosphorylation of the vector (see 3.4.6), pDNA was purified from the reaction 
mixture by using the MinElute Gel Extraction Kit according to the manufacturer’s instructions. 
300µl ERC buffer were added to the plasmid mixture, transferred onto a column and centri-
fuged at 10,000rpm for 1min. Then, DNA was washed with 750µl PE buffer and the column 
was dried at 13,000rpm for 1min. Finally, DNA was eluted with 20µl EB buffer and stored at -
20°C. 
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3.4.6. Dephosphorylation of vector 
The vector was dephosphorylated prior to the ligation reaction to prevent the backbone 
from spontaneous re-ligation. The dephosphorylation reaction was carried out at 37°C for 
30min and subsequently purified as described in 3.4.5.2. 
 
 Final concentration Volume 
pDNA  x µl 
CIAP [1U/µl] 0.04U/µl 2µl 
CIAP buffer [10x] 1x 5µl 
ddH2O ad 50µl x µl 
Final volume  50µl 
Table 3-7: Dephosphorylation reaction 
 
 
3.4.7. Ligation 
The required volumes of backbone and insert to achieve a suitable ratio in the ligation 
reaction were estimated visually by running a 1% agarose / ethidium bromide gel. The ligation 
reaction was carried out overnight at 16°C. 3’UTRs of Fra-1, Net and Dicer were ligated via 
XhoI and NotI cutting sites, 3’UTRs of c-Jun and Oct-1 via XhoI and PmeI. 
 
Ligation reaction Final concentration Volume 
T4 DNA Ligase [400U/µl] 20.0U/µl 1 µl 
Ligase buffer [10x] 1x 2 µl 
psiCHECK™-2 x µl 
insert 
ratio (vector: insert): 
1:5 – 1:8 x µl 
ddH2O ad 20µl x µl 
Final volume  20µl 
Table 3-8: Ligation reaction 
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For Net 3’UTR, a different strategy was applied. Since the amount of Net 3’UTR was 
too low from the PCR for direct digestion and subsequent cloning into psiCHECK™-2, the 
fragment was first cloned into TOPO vector (ZeroBlunt® Topo® PCR Cloning Kit). Ligation 
was carried out at 20°C, 30min, according to the ma nufacturer’s instructions. Positive colonies 
were selected, mini DNA preparations were made (see 3.4.9) and sequenced. Then, Net 
3’UTR was prepared in sufficient amount by restriction enzyme digestion and cloned into psi-
CHECK™-2. 
 
 
3.4.8. Transformation of chemically competent E. coli 
Ligation reaction was heated up to 65°C for 10min t o inactivate the ligase. Then, 2µl of 
the ligation mixture were transfected into 25µl of TOP10 chemically competent cells according 
to the manufacturer’s instructions. Bacteria were incubated with the plasmid solution on ice for 
30min, then heat-shocked at 42°C for 30sec and incu bated while shaking for 1h with pre-
warmed S.O.C. medium at 37°C. Subsequently, bacteri a were spread onto LB-agar plates 
containing the selective antibiotic and incubated at 37°C overnight to allow colony growth. 
 
 
3.4.9. Mini preparation of plasmid DNA 
Plasmid DNA was purified with the QIAprep® Miniprep Kit following manufacturer’s in-
structions. 7ml LB medium were inoculated with one colony from the agar plate (see 3.4.8) 
and were incubated at 37°C overnight. Then, bacteri a were pelleted and resuspended in 
250µl P1 buffer. For lysis, 250µl P2 buffer were added and the lysis reaction was stopped af-
ter 5min. Subsequently, 350µl N3 buffer were added and the mixture was centrifuged at 
13,000rpm for 10min. The clarified supernatant was centrifuged through a QIAprep spin col-
umn which was then washed with 500µl PB buffer and 750µl PE buffer. The column was dried 
at 13,000rpm, 1min. Finally, plasmid DNA was eluted with 30µl EB buffer. pDNA was stored at 
-20°C. 
 
 
3.4.10. Sequencing of reporter plasmids 
Plasmids were sequenced by GATC Biotech AG, Konstanz, to ensure absence of point 
mutations. 
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3.4.11. Maxi preparation of plasmid DNA 
Large amounts of pDNA were prepared with the Qiagen® Plasmid Purification Maxi Kit 
following the manufacturer’s instructions. 7ml LB medium were inoculated with either one col-
ony from the LB agar plate (see 3.4.8) or with bacteria culture, left over from the mini prepara-
tion (see 3.4.9). The culture was incubated at 37°C for 8h at 225r pm on a shaker. Then, the 
culture was transferred into 300ml LB medium and incubated further at 37°C for 12-14h at 
225rpm on a shaker. Then, the suspension was transferred into centrifuge tubes and bacteria 
were centrifuged at 6,000rpm for 15min at 4°C. The clarified supernatant was removed and 
the bacteria pellet was resuspended in 10ml P1 buffer, then lysed by adding 10ml P2 buffer at 
20°C for 5min. Subsequently, lysis was stopped with  10ml P3 buffer and the mixture was neu-
tralized at 4°C for 20min. Then, the supernatant co ntaining the plasmid DNA was clarified by 
centrifuging at 4°C for 30min at 13,000rpm before i t was transferred onto the column. After-
wards, the column was washed twice with 30ml GC buffer and pDNA was eluted with 15ml QF 
buffer into a Falcon tube containing 10.5ml isopropanol for precipitation. Subsequently, the 
pDNA dispersion was centrifuged at 4°C, 4,000rpm, 1 h. Finally, the pelleted pDNA was 
washed with ice-cold 70% ethanol twice and dissolved in 200µl TE buffer. pDNA was stored at 
-20°C. 
 
 
3.4.11.1. Cryoconservation and reactivation of bacteria 
In order to have permanent stocks of bacterial strains, bacteria were cryoconserved. 
800µl of an exponentially growing bacterial suspension were mixed with the same volume of 
86% glycerin and shock-frozen in liquid nitrogen. The strains were then stored at -80°C. For 
reactivation, a pipette tip was dipped into the glycerin culture and used to inoculate a LB-agar 
plate, which was subsequently incubated at 37°C ove rnight. 
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3.4.11.2. Plasmid maps 
 
 
 
 
 
 
 
 
3.5. Reporter gene analysis 
In reporter gene assays the Dual-Luciferase® Reporter Assay System was applied to 
analyze functional implications of miRNAs. The assay makes use of two luciferases: Firefly-
luciferase derived from firefly Photinus pyralis and Renilla-luciferase derived from sea pansy 
Renilla reniformis. The system benefits from the absence of human equivalents, the short half-
life time of mRNAs and proteins and the high sensitivity (de Wet et al., 1987). 
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The two luciferase enzymes catalyze the oxidation of their respective substrates, which 
is accompanied by light emission. The light intensities are directly proportional to the amount 
of luciferases. Therefore, the number of impulses indirectly allows quantification of the pro-
teins and conclusions about the biological activity of miRNAs. Since the substrates and the 
peak emission wavelengths are different, the activities of Firefly- and Renilla-luciferase can be 
determined in parallel. 
 
 
3.5.1. Transfection of reporter genes 
3.5.1.1. Transfection of plasmid DNA 
For reporter gene analysis, reporter constructs were transfected using Effectene™. Ef-
fectene® is a non-liposomal lipid reagent that forms micelle structures that incorporate con-
densed DNA which is then able to pass through the cell membrane. Transfections were done 
according to the manufacturer’s instructions including 4-6 biological replicates per experimen-
tal setup. Cells were seeded 24h prior to transfection in 6-well plates: “444” cells 1.3x105, 
“CGL3” and HeLa cells 3.5x105. Next day, medium was removed and replaced with 2.0ml 
fresh complete DMEM.  
For pAP-1-luciferase assays, for one single transfection, 95ng of pAP-1-Luc and 5ng of 
pRL-TK were mixed with EC buffer and 0.8µl enhancer and incubated at 20°C, 5min. Then, 
2.5µl Effectene were added, vortexed 10sec and incubated at 20°C, 10min, to allow formation 
of micelles. Then, the mixture was slightly agitated together with complete DMEM and finally 
the complete 300µl transfection mixture was added drop wise to the well. 
For psiCHECK™-2 luciferase assays, the protocol was slightly different due to the low 
amount of Effectene reagent. For one single transfection, 5ng of the respective psiCHECK-2 
construct were mixed with EC buffer and 0.08µl enhancer and incubated at 20°C, 5min. Then, 
0.25µl Effectene that had been diluted with EC buffer were added, vortexed 10sec and incu-
bated at 20°C, 10min. Then, the mixture was slightl y agitated together with complete DMEM 
and finally the complete 300µl transfection mixture was added drop wise to each well. 
To reduce errors in biological replicates, master mixes were prepared for all transfec-
tions. Next day, 24h later, cells were harvested (see 3.5.2). 
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3.5.1.2. Co-transfection of plasmid DNA and miRNA mimics 
For reporter gene analysis, reporter constructs and miRNA mimics were transfected 
using Lipofectamine™ 2000. Lipofectamine™ 2000 forms cationic liposomes that encapsu-
lated pDNA and miRNA mimics which were then able to pass through the cell membrane. 
Transfections were done according to the manufacturer’s instructions including 4 biological 
replicates per experimental setup. 1x104 “444” cells were seeded 24h prior to transfection in 
96-well plates. Next day, medium was removed and replaced with 50µl fresh DMEM only sup-
plemented with serum. 
For one single 96-well transfection, 0.2ng of psiCHECK2-3’UTR construct and 15pmol 
miRNA mimic (final concentration 150nM) were diluted in 25µl OPTI-MEM without additives. 
0.583µl Lipofectamine™ 2000 were diluted separately in the same volume of OPTI-MEM 
without additives and incubated for 5min. Then, both mixtures were combined, slightly agi-
tated and incubated for 20min. Finally, the complete 50µl transfection mixture was added drop 
wise to the well. 
 
 
3.5.2. Cell extracts for reporter gene analysis 
Cell extracts for reporter gene analysis were harvested 24h after transfection (see 
3.5.1). 6-well plates (see 3.5.1.1) were washed twice with 1xPBS. Then, 80µl of 1x Passive 
Lysis buffer (Dual-Luciferase® Reporter Assay kit) were added to each well and cells were 
scrapped and transferred into Eppendorf tubes. Cell suspensions were incubated for 30min to 
allow for complete cell lysis, then vortexed for 3sec and centrifuged at 13,000rpm for 2min. 
The clarified supernatants were transferred into fresh tubes and signal intensity was quantified 
immediately (see 3.5.3) or stored at -80°C. Alternatively, cells in 96-we ll plates (see 3.5.1.2) 
were lysed with 35µl of 1x Passive Lysis buffer after washing with 1xPBS. Lysis occurred 
while shaking on a Thermomixer at 4°C, for 1h. Subs equently, 15µl of the suspension were 
used for the measurement. All steps were carried out at 4°. 
 
 
3.5.3. Firefly- / Renilla-luciferase measurements 
Luciferase measurements were done with the Mithras plate reader and the MicroWin 
2000 software. 10µl of each extract were loaded onto a 96-well plate. LARII and Stop&Glow 
buffer were prepared according to the manufacturer’s instructions. The program was as fol-
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lows: injection of 50µl LARII, 2sec incubation, 10sec reading, injection of 50µl Stop&Glow, 
2sec incubation and 10sec reading. Readings were exported to a MS Excel file and analyzed. 
Results for pAP-1-luciferase assays are given as RLU [%] by dividing Firefly-luciferase 
readings with Renilla-luciferase readings. Graphics show the increase in percentage [%] com-
pared to a control treatment set to 100%. 
Results for psiCHECK™-2 luciferase assays are given as RLU [%] by first dividing 
Renilla-luciferase readings with Firefly-luciferase readings and second by dividing this figure 
with the one obtained from the control plasmid without an insert (psiCHECK™-2_empty). 
Graphics show the increase in percentage [%] compared to a control treatment set to 100%. 
 
 
3.6. RNA-interference (RNAi) 
RNA-interference is a mechanism by which genes are post-transcriptionally silenced 
either by endogenous or exogenous, artificial, double-stranded siRNA (small interfering RNA). 
siRNAs recognize their respective target genes via Watson-Crick base-pairing to mRNA re-
sulting in selective degradation of the mRNA and therefore inhibiting de-novo protein synthe-
sis (Elbashir et al., 2001; Meister and Tuschl, 2004). 
siRNAs were transfected with HiPerFect Transfection Reagent according to the manu-
facturer’s suggestions. 20µl of siRNA (40µM) were mixed with 1.0ml DMEM without additives 
and 40µl HiPerFect, vortexed 3sec and incubated at 20°C, 10min. Then, 2x10 6 cells of “444” 
or “CGL3” were seeded in a 60cm2 cell culture plate with a final volume of 7.0ml complete 
DMEM. Transfection solution was added drop wise to the cell suspension resulting in 8.0ml 
total volume and 100nM final siRNA concentration. Cell culture plates were agitated slightly 
and placed in the incubator. On day 2, 24h later, cells were trypsinized (see 3.1.1), counted 
(see 3.1.3) and plated in 6-well plates for reporter gene assays (see 3.5) or split in 20cm2 and 
60cm2 cell culture plates to obtain nuclear extracts (see 3.2.1) and whole cell extracts (see 
3.2.2) on day 4. 
 
 
3.6.1. Diagram of the workflow of a standard experiment 
All experiments requiring Drosha and Dicer knock-down and subsequent pDNA trans-
fection were carried out following this overview: 
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Figure 3-3: Workflow of standard experiment requiring depletion of Drosha and Dicer 
 
 
3.7. miRNA prediction software analysis 
To obtain a comprehensive list of miRNAs that are predicted to regulate c-Jun and Fra-
1, prediction software tools were used: TargetScan, PicTar, miRBase and DIANA-microT. 
TargetScan classifies its predictions in: 
conserved sites for miRNA families broadly conserved among vertebrates 
conserved sites for miRNA families conserved only among mammals 
poorly conserved sites and sites for poorly conserved miRNA families 
Predictions from all three categories were included in the common list. 
PicTar was searched by setting the parameters: 
“species” to “vertebrate” 
“dataset” to “target predictions for all human microRNAs based on conservation in mammals 
(human, chimp, mouse, rat, dog)”. 
All given predictions were included in the common list. 
miRBase was searched setting the parameter “genome” to “homo sapiens”. 
All given predictions were included in the common list. 
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DIANA-microT was used setting the “score threshold” to “7.3” which is considered to 
be a loose criterion and searching in “homo sapiens genome”. 
All predictions were included in the common list. 
Once the comprehensive list was assembled, the predicted miRNAs were ranked ac-
cording to the frequency of their respective nomination by the software programs and by the 
number of the predicted binding sites. The classification was as follows: 
4/4  predicted by all 4 search engines 
3/4 +double predicted by 3 search engines with 2 binding sites 
3/4  predicted by 3 search engines 
2/4 + double predicted by 2 search engines with 2 binding sites 
2/4  predicted by 2 search engines 
1/4 + double predicted by 1 search engine with 2 binding sites 
Locations of predicted miRNA binding sites in the 3’UTR are displayed in a table, see 7.2. 
 
 
3.8. Illumina miRNA array 
The Illumina miRNA array was performed by Dr. Bernhard Korn, Genomics and Pro-
teomis Core Facility, German Cancer Research Center. 
 
 
3.8.1. RNA analysis 
Total RNA was prepared according to 3.3.3 and subsequently checked by gel analysis 
using the Total RNA Nanochip assay on an Agilent 2100 Bioanalyzer. Only samples with RNA 
index values greater than 7 were selected for microRNA profiling. RNA concentrations were 
determined using the NanoDrop spectrophotometer. 
 
 
3.8.2. Probe labeling and Illumina BeadArray Hybridization 
The method is a modification of an assay that was developed for high-throughput gene 
expression profiling, the DASL® Assay (cDNA-mediated annealing, selection, extension and 
ligation, (Fan et al., 2004)). The miRNA method similarly targets specific sequences with sets 
of oligonucleotides that are extended, and then labeled during PCR amplification. If not stated 
otherwise, 200 ng of total RNA were first polyadenylated using Poly-A Polymerase, incubated 
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at 37°C for 60 min, then heat inactivated at 70°C f or 10 min. The introduced poly A tail was 
then used as a priming site for cDNA synthesis, incubated at 42°C for 60 min, then heat inac-
tivated at 70°C for 10 min. The primer used for cDN A synthesis was biotinylated and con-
tained a universal PCR primer sequence that was used later in the assay. After cDNA synthe-
sis, miRNAs were individually interrogated using specific oligonucleotides. A single miRNA-
specific oligo (MSO) is designed against each mature miRNA sequence, which consists of 
three parts: at the 5′-end is another universal PCR priming site; in the middle is an address 
sequence used for capturing the product on the array; and at the 3′-end is a miRNA-specific 
sequence. The second universal PCR priming site is shared among all MSO's, and each ad-
dress sequence is associated uniquely with each of the 470 miRNA targets (miRBase data-
base v9.1). As controls, central mismatch probes for miRNAs hsa-let-7a, let-7c, let-7f, miR-
152 and miR-182, and 3′-end mismatch probes for small nuclear RNAs RNU24 and RNU66 
were used. The subsequent assay process and array hybridization were performed as de-
scribed previously (Fan et al., 2004). Briefly, 15 µl of the cDNA synthesis reaction was added 
to 5 µl of the multiplexed MSO pool and 30 µl of a reagent containing streptavidin paramag-
netic particles, heated to 70°C, and allowed to ann eal to 40°C. All 470 human miRNAs were 
assayed simultaneously. After binding and washing, the annealed MSOs were extended 
through the cDNA primer, forming an amplifiable product. The extended oligos were eluted 
from the streptavidin beads and added to a PCR reaction, in which one of the universal prim-
ers was Cy3 labeled and the other universal primer was biotinylated. The PCR products were 
captured on streptavidin paramagnetic beads, washed and denatured to yield single-stranded 
fluorescent molecules to hybridize to the arrays. The universal arrays used for fluorescent re-
porting consist of capture oligos immobilized on beads and randomly assembled onto the 
ends of fiber optic bundles, which are arranged in a matrix to match a 96-well plate (Sentrix® 
Array Matrix, Illumina, (Fan et al., 2006)). The identity of each bead is determined before hy-
bridization to the miRNA assay product. Arrays were scanned on the BeadArray Reader, and 
automatic image registration and intensity extraction software was used to derive intensity 
data per bead type corresponding to each miRNA (Galinsky, 2003). 
 
 
3.8.3. Microarray data analysis 
The array intensity data were imported into Beadstudio version 3 (Illumina), a software 
package that permits visualization and normalization of the data. The quantile normalization 
method for all the analyses reported here was used (Chudin et al., 2006). miRNA expression 
statuses were assessed by signal intensity and p-values. The threshold was defined as signal 
intensity ≥ 400 and p-value ≤ 0.01. 
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4. Results 
4.1. Model system: HPV18-positive non-malignant and malignant cell lines 
To analyze the impact of miRNAs on the stoichiometry of AP-1 members in HPV-
positive cell lines with different phenotypes, an in vitro model system was applied. The cell 
system bases on the fusion of the HPV18-positive cervical carcinoma cell line HeLa with the 
male fibroblast cell strain GM77, thereby generating HeLa-fibroblast-hybrids, termed “444”. 
Inoculation into immuno-compromised mice showed that 444 cells are non-malignant 
(Stanbridge, 1984). However, 444 cells are genetically unstable that leads to segregants upon 
long-term in vitro cultivation. These segregants were referred as “CGL3” and display a tumori-
genic phenotype in nude mice (Stanbridge, 1984) (Fig. 4-1A). In non-malignant HeLa-
fibroblast-hybrids, AP-1 is mainly composed of c-Jun:Fra-1 heterodimers, whereas the malig-
nant counterpart CGL3 is characterized by reduced levels of c-Jun and c-Jun:c-Fos het-
erodimers (Soto et al., 1999) (Fig. 4-1B). 
 
A 
 
B 
 
Figure 4-1: Model system of non-tumorigenic and tumorigenic HPV18-positive cell lines 
(A) Fusion of the cervical carcinoma cell line HeLa with the male fibroblast cell strain GM77 generated non-
tumorigenic HeLa-Fibrobast-Hybrids (“444”). Confluent and enduring cultivation leads to their clonal segregants 
(“CGL3”), which possess a tumorigenic phenotype (Stanbridge, 1984; Soto et al., 1999). (B) AP-1 composition of 
both cell hybrids and the parental HeLa cells are displayed (Soto et al., 1999) 
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4.2. Differential expression of AP-1 members upon disruption of the miRNA bio-
genesis machinery 
miRNAs can post-transcriptionally inhibit gene expression by targeting mRNAs. Thus, 
a widely used strategy to detect such repressed genes is to deplete cells from the miRNA con-
taining effector complexes, miRISC and miRNP. This is achieved by knocking down key com-
ponents of the miRNA biogenesis machinery or of the effector complexes (Schmitter et al., 
2006; Kuehbacher et al., 2007; Lee and Dutta, 2007; Tang et al., 2007). Here, Drosha and 
Dicer, two miRNA processing enzymes, were knocked down using specific siRNAs against 
target sequences located in the ORFs (open reading frame). Following depletion of Drosha 
and Dicer, the expression of AP-1 family members was analyzed on mRNA and protein levels 
in order to decipher possible miRNA-regulated proteins (Fig. 4-2, 4-3). 
Drosha mRNA (Fig. 4-2, lane 1) and protein (Fig. 4-3) were steadily down-regulated 
with nearly 100% efficiency in all three cell lines after 72h post-transfection. Dicer protein was 
reduced to a lesser extent (Fig. 4-3), while Dicer mRNA was re-expressed at normal levels in 
444 and CGL3 cells (Fig. 4-2, lane 2), compared to control transfections. As exemplified by 
let-7a Northern blotting in 444 samples (Fig. 4-4), the knock-downs of Drosha and Dicer led to 
a substantial decrease in mature miRNAs. Let-7a was analyzed because it belongs to the let-
7 family, let-7a-g and let-7i that is known to regulate Dicer (Tokumaru et al., 2008). 
In order to demonstrate functional consequences on endogenous miRNA target genes, 
the positive control Dicer, which is regulated by the let-7 family (Tokumaru et al., 2008), was 
analyzed. Upon depletion of Drosha, Dicer was increased on mRNA levels in 444 and CGL3 
cells (Fig. 4-2, lane 2) and also on protein levels in 444, CGL3 and HeLa cells (Fig. 4-3). 
Besides the positive control, the transcription factor Oct-1 was unresponsive in all cell 
lines. Oct-1, also known as POU2F1, is a member of the POU transcription factor family 
(Phillips and Luisi, 2000). Oct-1 mRNA levels did not change upon Drosha or Dicer down-
regulation neither 444 nor CGL3 cells (Fig. 4-2, lane 3). Additionally, Oct-1 protein also re-
mained unaltered, as shown in EMSA assays for 444, CGL3 and HeLa cells (see 4.3, Fig. 4-
5A). Therefore, Oct-1 served as a negative control, thereby predefining the threshold levels, 
where mRNA changes were not considered to be significant. Additionally, Oct-1 proved speci-
ficity for the observed effects. 
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Figure 4-2: Changes in mRNA levels upon disruption of the miRNA pathway 
(A) 444 and (B) CGL3 cells were treated for 72h with siLuciferase (black bars), siDrosha (white bars) and siDicer 
(grey bars) RNA. qRT-PCRs of the indicated genes were preformed and normalized against GAPDH. Relative in-
creases in signal intensities compared to siLuciferase for each gene were plotted in percentage. Error bars repre-
sent s.d. from three independent experiments. 
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The mRNA analysis of AP-1 family members (Fig. 4-2) revealed that c-Jun (lane 4) 
and JunB (lane 5) levels were up-regulated in 444, while in CGL3 cells only JunB was up-
regulated upon siDrosha treatment. JunD (lane 6) and JDP2 (lane 7) levels did not change in 
either cell line. Fra-1 mRNA (lane 8) was up-regulated in 444 and to a lesser extent also in 
CGL3 cells, whereas Fra-2 (lane 9) was only increased in CGL3 cells under siDrosha treat-
ment. c-Fos (lane 10) and ATF-2 (lane 12) were unaltered in 444 cells, and FosB (lane 11) 
was slightly increased. Contrarily, CGL3 cells displayed a slight reduction for c-Fos (lane 10) 
and ATF-2 (lane 12) mRNA levels, while FosB was slightly reduced upon depletion of 
siDrosha and unchanged upon depletion of Dicer. The transcription factor Net (lane 13), 
which is a transcriptional repressor of c-fos (van Riggelen et al., 2005), was only up-regulated 
in the non-tumorigenic cell line 444 upon depletion of Dicer. 
 
 
Figure 4-3: Changes in protein levels upon disruption of the miRNA pathway 
12-15µg nuclear protein extract of 444, CGL3 and HeLa cells were used for all Western Blots, except 15µg whole 
cell lysate was used for Dicer. Actin served as a loading control. Sizes in kDa are indicated. Proteins were re-
solved in 6-10% Polyacrylamid gels, followed by incubation with the indicated primary antibodies. Protein amounts 
were assessed by chemiluminescence. 
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Furthermore, protein extracts from the 
same experiments were also used to analyze AP-1 
family members by Western blotting to monitor, 
whether the observed changes in mRNA also re-
sulted in different protein levels. Additionally, pa-
rental tumorigenic HeLa cells were also included in 
the analysis (Fig. 4-3). 
c-Jun was up-regulated in 444 and HeLa 
cells, whereas CGL3 did not show any difference. 
Fra-1 was up-regulated in 444 and CGL3, whereas 
it was unchanged in HeLa cells. ATF-2 was un-
changed in 444 and CGL3 and slightly increased in 
HeLa cells. c-Fos did not change in the two hybrid 
cell lines, while it was reduced in HeLa cells. 
 Taken together, the mRNA and protein 
data revealed that a subset of AP-1 members was 
differentially regulated upon knock-down of the 
miRNA biogenesis pathway (Tbl. 4-1). Concerning 
the AP-1 proteins c-Jun, Fra-1 and c-Fos, which 
are important for HPV-transcription in the cell sys-
tem, the comparative analysis displayed some dif-
ferences: Fra-1 was up-regulated in 444 and CGL3 
cells. c-Jun was increased only in the parental 
HeLa cells and in the non-tumorigenic hybrids. 
Contrarily, on mRNA level, CGL3 cells showed a 
slight reduction of c-Fos, which was, however, 
largely reduced in HeLa cells on protein levels. 
 
 
 
 
 
 
 
 
Figure 4-4: Reduction of let-7a upon 
knockdown of Drosha or Dicer 
444 cells were transfected for 72h with si-
Control, siDrosha and siDicer RNA. Abun-
dance of mature let-7a was analyzed by 
Northern blotting of 20µg total RNA. RNA 
quality was monitored by polyacrylamide gel 
electrophoresis; 5S, 18S, 28S ribosomal 
RNA were used as loading controls. 
Table 4-1: AP-1 members are differ-
entially modulated upon knockdown 
of Drosha or Dicer 
The table gives a summary on modulated 
levels of AP-1 family members, which are 
confirmed by Western blotting, upon knock-
down of Drosha and Dicer. +, increased; 0, 
unchanged; -, decreased levels. 
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4.3. Modulation of AP-1 composition upon disruption of the miRNA pathway 
Having shown that Drosha / Dicer knock-down affected c-Jun, Fra-1 and c-Fos levels, 
the possible consequences for amount, composition and activity of AP-1 dimers were studied. 
To address the question if the abundance of functional AP-1 dimers was altered, electro-
mobility-shift-assays (EMSA) were employed (Fig. 4-5A). In 444 cells, an enhanced binding of 
AP-1 to its consensus sequence after Drosha and Dicer knock-down was observed, whereas 
CGL3 and HeLa cells did not show this effect. The negative control Oct-1 remained unaltered 
in all three cell lines. The slight up-regulation of sample 444 siDr was not considered to be 
significant. 
Additionally, the composition of AP-1 dimers was monitored by EMSA with super shift-
ing antibodies (Fig. 4-5B,C,D). In 444 cells, the supershift showed that the enhanced AP-1 
binding is mediated by increased dimerization between c-Jun:c-Jun homodimers c-Jun:Fra-1 
heterodimers (Fig. 4-5B). c-Fos incorporation did not change, as expected. In CGL3 cells, 
however, the increase of Fra-1 protein (Fig. 4-3) did not result in an enhanced incorporation 
into the AP-1 complex (Fig.4-5C). Additionally, c-Jun and c-Fos proteins in the AP-1 complex 
were not altered, as expected from unchanged protein levels. In HeLa cells, the incorporation 
of Fra-1 was not altered (Fig. 4-5D), while c-Jun was up-regulated. c-Fos, however, was re-
duced, reflecting down-regulation of c-Fos protein as shown by Western blotting (Fig. 4-3). 
 
A 
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Figure 4-5: Changes in AP-1 levels and composition upon disruption of the miRNA pathway 
AP-1 binding and composition were analyzed by EMSA (A) “shift-“ and (B,C,D) “super-shift-” analysis. 2µg nuclear 
extracts from figure 4-3 were incubated with 10,000 cpm 32P-radiolabeled AP-1 / Oct-1 consensus sequence. For 
super-shift reactions, 2µg antibody against p-c-Jun, Fra-1 or c-Fos were added. The analysis was performed in 
5.5% native polyacrylamid gels, followed by autoradiography. 
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4.4. Changes in AP-1 activity upon disruption of the miRNA biogenesis machinery 
To answer the question, if 
differential AP-1 binding in EMSAs 
upon depletion of Drosha and Dicer 
(Fig. 4-5A) affects the transcrip-
tional activity of AP-1, the reporter 
plasmid pAP-1 was used. In this 
vector, the expression of Firefly 
luciferase is controlled by five AP-1 
consensus sequences, also termed 
“TRE”-sites (TPA (12-O-
tetradecanoylphorbol-13-acetate) 
responsive element) (Tseng and 
Verma, 1995), that are fused to a 
core promoter only containing a 
TATA box. 
444 cells showed an about 
3-fold increased expression of Fire-
fly luciferase after knock-down of 
Drosha and Dicer. CGL3 and HeLa 
cells, however, did not show en-
hanced AP-1 transcriptional activity under either treatment (Fig. 4-6). 
These results indicate that the transcriptional activity of AP-1 is selectively modulated 
by miRNAs in 444 cells, but not in CGL3 and HeLa cells, through a direct or an indirect effect. 
 
 
4.5. c-Jun, Fra-1 and Net are direct targets of miRNAs 
Previous experiments have shown that AP-1 members are differentially and selectively 
modulated by miRNAs in the non-malignant cell lines 444 and in the malignant cell lines CGL3 
and HeLa. However, the question, whether the modulation was achieved through a direct or 
an indirect effect, has not been addressed. A commonly used approach is the cloning of the 
full-length 3’UTR (untranslated region) of the respective gene behind a luciferase reporter 
gene in order to generate a Luciferase-target gene 3’UTR fusion transcript (Garzon et al., 
2006; Lee et al., 2006; Schultz et al., 2008; Tay et al., 2008). Direct interactions of miRNAs 
 
Figure 4-6: Higher AP-1 activity in 444 upon disrup-
tion of the miRNA pathway 
444, CGL3 and HeLa cells were transfected for 72h with si-
Control (black bars), siDrosha (white bars) and siDicer (grey 
bars) RNA. 24h prior to harvest, an AP-1 responsive reporter 
plasmid, pAP-1 Firefly-luciferase, and a control plasmid, pRL-
Renilla-luciferase, were transfected. Relative increases in sig-
nal intensities compared to siControl were plotted in percent-
age. Error bars represent s.d. from 4 replicates. 
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and putative target genes are assessed by luciferase assays based on selective degradation 
or translational repression of Luciferase-target gene 3’UTR fusion transcripts. 
The most comprehensive data encompassing results on mRNA, protein and biological 
functionality were obtained for c-Jun and Fra-1. In addition, besides c-Fos, both proteins con-
stitute the important AP-1 family members regulating HPV-transcription. Therefore, further 
analysis focused on c-Jun and Fra-1. Additionally, Net, the transcriptional repressor of c-Fos 
(van Riggelen et al., 2005), was also further examined, since Net showed differential regula-
tion in the non-malignant and malignant hybrids (Fig. 4-2). 
 
The full-length 3’UTRs of c-Jun, Fra-1, Net, Dicer (positive control) and Oct-1 (negative 
control) were cloned downstream of Renilla luciferase. The assay was done in 444 cells that 
had already shown the up-regulation of c-Jun, Fra-1 and Net at mRNA and / or protein levels 
(Fig. 4-2, 4-3) after knock-down of Drosha and Dicer. Depletion of Drosha led to a ~1.5 fold 
and depletion of Dicer to a ~2.5 fold increased activity of the reporter gene Renilla-Dicer 
3’UTR, as expected for the positive control. The negative control Renilla-Oct-1 3’UTR showed 
only marginal effects (Fig. 4-7). The activities of Renilla-c-Jun 3’UTR and Renilla-Net 3’UTR 
A B 
 
 
Figure 4-7: c-Jun-, Fra-1- and Net-3’UTR reporter genes are responsive to miRNA regulation 
(A) Full-length 3‘UTRs of Dicer, Oct-1, c-Jun, Fra-1 and Net were cloned into psiCHECK2 to give rise to a fusion 
transcript of Renilla-target gene 3‘UTR; the internal Firefly-luciferase gene served as a normalization control. 
(B) 444 cells were transfected for 72h with siControl (black bars), siDrosha (white bars) and siDicer (grey bars) 
RNA. 24h prior to harvest, the respective psiCHECK2-3‘UTR plasmid was transfected. Values were normalized 
against the empty plasmid. Relative increases in signal intensities compared to siControl for each gene were plot-
ted in percentage. Error bars represent s.d. from 3 independent experiments. 
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were only significantly increased upon knock-down of Dicer, whereas the activity of Renilla-
Fra-1 3’UTR was augmented under both treatments. 
Taken together, these results demonstrated that c-Jun, Fra-1 and Net are directly 
regulated by miRNAs in non-malignant 444 cells. 
 
 
4.6. Identification of putative miRNAs regulating c-Jun and Fra-1 
In order to identify the miRNAs that regulate c-Jun and Fra-1, a bioinformatics ap-
proach was conducted by using the prediction software tools miRBase (Enright et al., 2003), 
TargetScan (Lewis et al., 2005; Grimson et al., 2007; Friedman et al., 2009), DIANA microT 
(Maragkakis et al., 2009) and PicTar (Krek et al., 2005; Lall et al., 2006). Thereby, TargetScan 
bases its predictions on the presence of conserved 8mer and 7mer sites within 3’UTRs that 
match the seed region, nucleotides 2-7 from the 5’ end, of each miRNA (Lewis et al., 2005). 
PicTar calculates “binding scores” according to sequence conservation of the 3’UTRs and to 
optimal free energies that result from binding with the seed region and from additional hybridi-
zations in the middle or at the 3’ end of the miRNA (Krek et al., 2005). DIANA microT takes 
into account sequence conservation for up to 27 species of the MRE (miRNA recognition ele-
ment), which is the seed sequence that is allowed to be of 6 to 9 nucleotides of length. Addi-
tional binding via the 3’ end of the miRNA is also considered (Maragkakis et al., 2009). miR-
Base predictions rely on the presence of a conserved seed sequence, for which up to 37 ge-
nomes are analyzed, and on the estimated accessibility via RNA folding and thermodynamic 
stability (Enright et al., 2003; Griffiths-Jones et al., 2006; Griffiths-Jones et al., 2008). 
Putative miRNAs were classified according to the frequency of predictions and accord-
ing to the number of predicted binding sites within the respective 3’UTR. For c-Jun, miR-139-
5p, -340, -495, -200b, -32 and -522 are the most likely candidates (Tbl. 4-2A). For Fra-1, miR-
34a, -449a, - 19a, -22, -34c-5p, -138, -149 and -593 are the most likely candidates (Tbl. 4-
2B). Due to the high number of predicted miRNAs, the 3’UTRs of c-Jun and Fra-1 were dis-
sected. Single segments were used in the luciferase reporter system to identify the responsi-
ble segments that harbor the miRNA binding sites and to decrease the number of predicted 
miRNAs (Tbl. 4-3). Luciferase assays were conducted in 444 cells that showed the repressive 
effect of miRNAs for both proteins. Although abrogation of Drosha and Dicer led to increased 
levels of c-Jun mRNA (Fig. 4-2) and protein (Fig. 4-3), only depletion of Dicer gave clear re-
sults in the luciferase assay for unknown reasons (Fig. 4-7). For Fra-1, both treatments led to 
equal effects in the luciferase assay (Fig. 4-7); therefore 444 cells were depleted from Drosha 
to analyze Fra-1 segments and from Dicer to analyze c-Jun segments. 
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For all segments of c-Jun and Fra-1, the relative increases compared to control trans-
fections exceeded the relative increases of the full-length 3’UTR reporter constructs, which 
served as positive controls (Fig. 4-8). Fra-1 segment 3 was the only exception that showed a 
similar increase compared to the Fra-1 full-length 3’UTR construct. Thus, the assays revealed 
that every segment of the 3’UTRs of c-Jun and Fra-1 harbors at least one miRNA binding site. 
Therefore, the number of putative miRNAs, which potentially regulate c-Jun and Fra-1, could 
not be reduced. 
 
 
 
Table 4-2: Bioinformatics analysis of c-Jun and Fra-1 for putative, regulatory miRNAs 
The prediction engines miRBase, TargetScan, PicTar and DIANA microT were searched for miRNAs that poten-
tially regulate (A) c-Jun and (B) Fra-1. Predicted miRNAs were clustered according to the frequency of citation: 
(4/4) predicted by 4 out of 4 search engines, (3/4 + double) predicted by 3 out of 4 search engines with at least 
two binding sites, (3/4) predicted by 3 out of 4 search engines, (2/4 + double) predicted by 2 out of 4 search en-
gines with at least two binding sites, (2/4) predicted by 2 out of 4 search engines, (1/4 + double) predicted by 1 out 
of 4 search engines with at least two binding sites. hsa-miR, homo sapiens miRNA 
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Table 4-3: Location of predicted miRNAs within the 3’UTRs of c-Jun and Fra-1 
c-Jun and Fra-1 3’UTRs were divided into (A) four segments for c-Jun and (B) three segments for Fra-1. Positions 
(Pos.) indicate start and end of each segment; total length of each segment is displayed. All segments were over-
lapping with neighboring segments with ~40bp. First segments started within CDS. For detailed sequence align-
ments see chapter 7.2. 
Predicted miRNAs from table 4-2 were localized within (C) the four segments of c-Jun 3’UTR and within (D) the 
three segments of Fra-1 3’UTR. 
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Figure 4-8: All 3’UTR segments of c-Jun and Fra-1 are responsive to miRNA-mediated regula-
tion 
Full-length 3‘UTRs of c-Jun and Fra-1 were dissected and cloned into psiCHECK2 to give rise to a fusion tran-
script of Renilla-3‘UTR segment; the internal Firefly-luciferase gene served as a normalization control. c-Jun 
3’UTR was divided into 4 segments, Fra-1 3’UTR into 3 segments. 
444 cells were transfected for 72h with siControl (black bars), siDrosha (white bars) or siDicer (grey bars) RNA. 
24h prior to harvest, the respective psiCHECK2-3‘UTR plasmid was transfected. Values were normalized against 
the empty plasmid. Relative increases in signal intensities compared to siControl for (A) c-Jun 3’UTR segments 
and (B) Fra-1 3’UTR segments were plotted in percentage. Error bars represent s.d. from 4 replicates. 
 
 
 
4. Results  89 
4.7. miRNA expression array of 444 and CGL3 cells 
Previous analysis revealed a com-
prehensive list of candidate miRNAs pre-
sumably regulating c-Jun and Fra-1. In or-
der to minimize the number of candidates, 
miRNAs that were not expressed in the cell 
system were not considered for further 
analysis. 
A miRNA expression profile with 470 
miRNAs was performed using 444 and 
CGL3 cells. The threshold for a reliable 
miRNA expression was defined as p-value 
≤ 0.01 and signal intensity ≥ 400, which 
was not a strict criterion, since signal inten-
sities ranged from 200 to 35,000. A miRNA 
was considered to be differentially ex-
pressed, when there were at least +/- 1.5 
fold changes of signal intensities of CGL3 
compared to 444 cells. The array displayed 
general differences between the two cell hybrids, with 275 expressed miRNAs in 444 and 252 
expressed miRNAs in CGL3 cells, of which 229 miRNAs were commonly expressed in both 
cell hybrids (Fig. 4-9). From the 229 commonly expressed miRNAs, in CGL3 cells, 99 
miRNAs were up-regulated and 15 miRNAs were down-regulated compared to 444 cells, 
whereas 115 miRNAs were expressed in comparable amounts. 
With respect to c-Jun that is regulated by miRNAs in 444 cells, only a miRNA, which is 
expressed in 444, but not in CGL3 cells, might be responsible for the regulation, since it was 
shown that c-Jun remained unaltered upon disruption of the miRNA pathway in CGL3 cells 
(Fig. 4-3). In this study, miR-495 was the only miRNA that was not expressed in the tumori-
genic cell line CGL3 (Tbl. 4-4). Fra-1 was equally up-regulated in both cell lines after knock-
down of the miRNA biogenesis pathway (Fig. 4-3); therefore, the reasoning is different. A sin-
gle miRNA that is expressed in both cell lines could repress Fra-1. Furthermore, if a set of 
miRNAs target Fra-1, the combination of miRNAs might differ in number and in contribution, 
respectively. For Fra-1, these criteria are fulfilled by a subgroup of candidate miRNAs that is 
still numerous (Tbl. 4-4). On the basis of these assumptions, further experiments focused on 
c-Jun, in order to identify a regulatory miRNA. 
 
 
Figure 4-9: The miRNome of 444 and CGL3 
cells partially overlaps 
An “Illumina” miRNA expression array for 444 and 
CGL3 cells reveals the number of totally expressed 
miRNAs that are partial equally or partial uniquely ex-
pressed in each cell hybride. A miRNA was consid-
ered to be expressed, if p-value ≤ 0.01 and signal in-
tensity ≥ 400, and considered to be differentially ex-
pressed, when changes were at least +/- 1.5 fold. 
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Table 4-4: miR-495 is the only differentially expressed miRNA putatively regulating c-Jun 
An “Illumina” miRNA expression array for 444 and CGL3 cells displays the signal intensities for putative, regula-
tory miRNAs of c-Jun and Fra-1. (A) Read-outs for all candidate miRNAs are shown, (B) read-outs for candidate 
miRNAs are shown that are above the threshold. The threshold was defined as p-value ≤ 0.01 and signal intensity 
≥ 400; not anal. = not analyzed (not included in the array). 
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4.8. Detailed analysis of predicted regulatory miRNAs of c-Jun 
The analysis of the miRNA 
expression array for the most prob-
able candidates possibly regulating 
c-Jun showed that miR-495 was dif-
ferentially expressed in 444 and 
CGL3 cells (Tbl. 4-4). In order to 
confirm the data from the miRNA 
profiling, the expression of mature 
miRNAs was indirectly confirmed by 
expression analysis of miRNA pre-
cursor forms, primary miRNA and 
precursor miRNA, by semi-
quantitative RT-PCR. The absence 
of a precursor form excludes the 
presence of a mature miRNA, but 
not vice versa as discussed in 5.6. 
Besides miR-495, other predicted 
miRNAs for c-Jun segment 2 were 
investigated: miR-32, miR-92a and 
miR-340. Let-7a served as a posi-
tive control. RT-PCR analysis showed that, of all analyzed miRNAs, miR-495 was the only 
miRNA which was selectively expressed in 444 cells (Fig. 4-10). This confirmed the data from 
the expression array indicating that let-7a, miR-32, -92a and -340 are expressed in both cell 
hybrids, whereas miR-495 is only expressed in the non-tumorigenic cell hybrids (Tbl. 4-4). 
Furthermore, the 3’UTRs of c-Jun of 444 and CGL3 cells were sequenced to exclude 
sequence variations that could influence miRNA binding sites. SNPs (single nucleotide poly-
morphisms) at the genomic level would be transcribed into an altered mRNA sequence and 
could abolish or generate miRNA binding sites (Clop et al., 2006; Saunders et al., 2007; Chen 
et al., 2008). Sequences were identical apart from a point mutation (GT) and a deletion of a 
G, which were both identified in segment 1 (Fig 4-11). However, these sequence variations do 
not overlap with predicted miRNA binding sites, and hence do presumably not abrogate 
miRNA-mediated repression. Whether these mutations generated new miRNA binding sites, 
was not investigated. 
 
Figure 4-10: miR-495 is only expressed in 444 cells 
Expression of primary- and precursor miRNAs in 444, CGL3 
and HeLa cells were analyzed by semi-quantitative RT-PCR. 
RNA quality was monitored by agarose gel electrophoresis; 
gapdh served as a control. 28S and 18S ribosomal RNAs and 
sizes in bp are indicated. 
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In conjunction with the high score of miR-495 in the bioinformatics prediction analysis 
and the opposing observations of the regulatory effect on c-Jun by miRNAs and the selective 
expression of miR-495 in 444 cells, miR-495 was a promising candidate to regulate c-Jun. 
 
 
 
Figure 4-11: Two point mutations in c-Jun 3’UTR of CGL3 compared to 444 cells 
Sequencing of the full-length 3’UTRs of c-Jun from 444 and CGL3 cells reveals one point mutation (GT) and 
one deletion (G) in CGL3 compared to 444. Mutations are localized in segment 1 (Tbl. 4-3C). The alignment of the 
first 360nt of c-Jun 3’UTR (total length 1284nt) is shown. 
 
 
4.9. Overexpression of miR-495 does not repress Renilla-cJun 3’UTR reporter gene 
activity 
The broad analysis of several miRNAs, which were predicted to regulate c-Jun, 
pointed to miR-495. In order to test, whether miR-495 does repress c-Jun, “miRIDIAN Mimic” 
miR-495 was co-transfected with the Renilla-c-Jun 3’UTR reporter constructs in 444 cells. 
Mimic let-7a / Renilla-Dicer 3’UTR reporter construct served as a positive control. The 
luciferase assay showed a strong decrease for the Dicer 3’UTR construct, whereas miR-495 
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did neither repress Renilla-c-Jun 3’UTR full-length nor Renilla-c-Jun 3’UTR segment 2 (Fig. 4-
12). This shows that miR-495 does presumably not regulate c-Jun. 
 
 
Figure 4-12: miR-495 does not repress Renilla-c-Jun 3’UTR reporter constructs 
444 cells were co-transfected with 150nM “miRIDIAN Mimic” control RNA (black bars), mimic let-7a RNA (white 
bar) or mimic miR-495 RNA (grey bars) and 0.2ng of the indicated Renilla-3‘UTR reporter plasmids. 24h after 
transfection, samples were analyzed with the Dual-Luciferase® Reporter Assay kit. Values for Renilla-luciferase 
were normalized against the internal Firefly-luciferase. Relative changes of signal intensities compared to mimic 
Control RNA were plotted in percentage. Error bars represent s.d. from 4 replicates. 
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5. Discussion 
5.1. Depletion of Drosha and Dicer alters the abundance of certain AP-1 members 
In the present study the question was addressed, whether miRNAs can regulate the 
transcription factor AP-1, a master regulator of many cellular processes like proliferation and 
neoplastic transformation (Angel and Karin, 1991; Eferl and Wagner, 2003). Besides studying 
different AP-1 subunits, the analysis also involved transcriptional regulators of AP-1 subunits. 
The transcriptional repressor Net, which controls c-fos expression (van Riggelen et al., 2005), 
and JDP2 (Jun dimerization protein 2), which represses c-jun expression (Jin et al., 2002; 
Heinrich et al., 2004) was also investigated. Oct-1, also known as POU2F1, is a member of 
the POU transcription factor family (Phillips and Luisi, 2000), and was used as control. 
 
It is a widely used strategy to detect miRNA-regulated target genes by knocking down 
proteins of the miRNA pathway: Drosha and Dicer (Kuehbacher et al., 2007; Lee and Dutta, 
2007), Dicer (Tang et al., 2007), Dicer and Ago1-4 (Schmitter et al., 2006), Drosha and Ago1-
2 (Rehwinkel et al., 2006). Disruption of the miRNA pathway by depletion of Drosha and Dicer 
affected significantly the abundance of miRNAs in the cell system, as exemplified by Northern 
blotting of let-7a in 444 cells (Fig. 4-4). The reduction of mature let-7a was in agreement with 
previous observations in HUVEC (Kuehbacher et al., 2007) and HeLa cells (Lee and Dutta, 
2007). 
Subsequent changes in mRNA or protein levels of putative miRNA targets could arise 
from direct or indirect effects. A mRNA transcript that is a direct target harbors one or several 
miRNA binding sites in its CDS (coding sequence) (Tay et al., 2008) and / or 3’UTR (untrans-
lated region) (Krek et al., 2005), to which miRNAs hybridize. Thereby, miRNAs guide the ef-
fector complexes miRISC (miRNA induced silencing complex) or miRNP (miRNA ribonucleo-
protein complex) that subsequently suppress target transcripts, as already described in chap-
ter 1.3.2. 
Besides such direct effects, also indirect effects must be considered, especially since 
the depletion of Drosha and Dicer leads to an impairment of the whole miRNome. Conse-
quently, many scenarios are possible where the level of a certain protein is indirectly affected 
by miRNAs that directly target regulatory proteins of the protein of interest. For example, miR-
29b was reported to repress the transcription factor Sp1 (Garzon et al., 2009), which in turn 
positively regulates the transcription of IL-10 (interleukin-10) (Larsson et al., 2009). Conse-
quently, miR-29b might indirectly regulate IL-10 expression. 
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In order to monitor, whether the de-
pletion of Drosha or Dicer led to functional 
effects on a known direct miRNA target, 
Dicer was analyzed (Forman et al., 2008; 
Tokumaru et al., 2008). The cytoplasmic 
RNAse III-type protein Dicer, which is a key 
component of the miRNA biogenesis path-
way (Bernstein et al., 2001; Hutvágner et 
al., 2001), is also regulated by miRNAs, 
namely by let-7 through three binding sites 
in the CDS (Forman et al., 2008) and one 
binding site in the 3’UTR (Tokumaru et al., 
2008). Genes are considered to be directly 
targeted by miRNAs, when mRNA levels 
are increased in a range of 1.5 to 2-fold 
upon abrogation of the miRNA biogenesis 
machinery (Rehwinkel et al., 2006; Schmit-
ter et al., 2006). In this study, the direct tar-
get Dicer was increased in 444 and CGL3 
cells upon knock-down of Drosha within this 
range (Fig. 4-2, lane 2). 
 
Regarding the analyzed proteins, in 
444 cells (Fig. 4-2A) c-Jun, JunB, Fra-1 
and the transcriptional repressor Net (only 
siDicer treatment) showed mRNA levels 
within this range of 1.5- to 2-fold induction, and were therefore considered to be regulated by 
miRNAs. In CGL3 cells (Fig. 4-2B) the AP-1 members Fra-1 and Fra-2, which were only re-
sponsive to depletion of Drosha, showed increased levels, though they were moderate com-
pared to 444 cells (Tbl. 5-1). 
The observation that Net in 444 cells was only responsive to depletion of Dicer sug-
gests that a transient knock-down might not be sufficiently efficient to inhibit all miRNAs. 
Some miRNAs might have a higher stability, which exceeds transient knock-downs. Similarly, 
it was found in HUVEC cells that upon transient depletion of Drosha or Dicer only a subset of 
miRNAs was reduced and that these reduced miRNAs were not always similarly reduced in 
both knock-downs (Kuehbacher et al., 2007). Another study reported similar observations in 
colorectal cancer cells (Cummins et al., 2006). Insufficient down-regulation of Dicer in CGL3 
 
Table 5-1: Transcription factors are partially 
differentially regulated by miRNAs 
The table gives an overview on modulated levels of 
AP-1 family members and of other transcription fac-
tors (except Dicer), which were found in qRT-PCR 
analysis, upon knock-down of Drosha and Dicer. Posi-
tive control (Dicer) and negative control (Oct-1) are 
highlighted in blue. +, regulated by miRNAs; 0, not 
regulated by miRNAs. For further details, see text. 
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cells might also explain why Fra-1 and Fra-2 were not up-regulated to the same extent as 
upon depletion of Drosha. 
Concerning the other analyzed genes, they displayed no or only minor changes and 
were then considered not to be direct targets of miRNAs, although it is possible that regulatory 
miRNAs for these genes were not affected by this experimental approach, see Tbl. 5-1. Initial 
experiments also included the oncoproteins HPV18 E6 and E7 that remained unaltered indi-
cating that they are not subject to direct or indirect regulation by miRNAs in 444 cells, data not 
shown. 
 
The levels of c-Jun, Fra-1 and c-Fos in 444 and CGL3 cells upon depletion of Drosha 
and Dicer were further confirmed on protein levels by Western blotting (Fig. 4-3) and were 
found to reflect the observed mRNA levels. Additionally, the analysis of HeLa cells revealed 
elevated levels of c-Jun and unchanged levels of Fra-1, while c-Fos was reduced (Fig. 4-3). 
Since Fra-1 is regulated by miRNAs in both hybrid cell lines, but not in parental HeLa 
cells, this suggests that this kind of regulation is derived from the other parental cell line, 
GM77. Contrarily, c-Fos is indirectly regulated in HeLa cells, whereas both hybrids did not 
show this regulation indicating that the fusion of HeLa with GM77 cells probably also impaired 
this regulation. 
c-Fos is the only AP-1 subunit, for which regulating miRNAs were described up to now 
(Lee et al., 2006; Li et al., 2009). Based on the concept that direct targets of miRNAs are up-
regulated following depletion of Drosha and Dicer, the observed down-regulation of c-Fos in 
HeLa cells (Fig. 4-3) suggests an indirect effect as already discussed above. Different scenar-
ios are possible, which would explain this observation: silencing of c-fos promoter by up-
regulated transcriptional repressors that act in trans or by enhanced heterochromatinization of 
the promoter region that acts in cis. Besides differential transcriptional regulation, post-
transcriptionally, c-Fos mRNA could be faster degraded, mediated by AREs (adenylate uridy-
late-rich elements) and mCRDs (major protein-coding region determinant of instability) in the 
3’UTR of c-Fos (Chen and Shyu, 1995; Grosset et al., 2000; Chen et al., 2002). Additionally, 
factors that negatively regulate c-Fos protein levels could contribute to the down-regulation. 
In this study, Net, a transcriptional repressor of the c-fos promoter, was analyzed in 
444 and CGL3 cells (Giovane et al., 1997; van Riggelen et al., 2005). It was shown that Net is 
a direct target of miRNAs (Fig. 4-7) in 444 cells, and that its increase (Fig. 4-2A, lane 13) did 
not result in elevated c-Fos levels (Fig. 4-2A, lane 10), possibly because the increase was not 
sufficient to repress c-fos transcription or that Net was phosphorylated and consequently did 
not act as a repressor (Ducret et al., 2000). In HeLa cells, however, further analysis will be 
necessary to decipher the miRNA-mediated mechanism, by which c-Fos is regulated. 
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5.2. Depletion of Drosha and Dicer modulates AP-1 composition and activity 
5.2.1. Modulation of AP-1 composition shown by EMSA and super shift-analysis 
The observed changes in protein levels resulted in modulation of AP-1 composition, 
amount and activity. In 444 cells, the increase of c-Jun and Fra-1 proteins led to an increased 
formation of c-Jun:c-Jun homodimers and c-Jun:Fra-1 heterodimers, as shown by EMSA (Fig. 
4-5A) and “super shift-“ analysis (Fig. 4-5B). 
CGL3 cells did not display any differences of AP-1 composition or formation (Fig. 4-
5A), as expected from unchanged levels of c-Jun and c-Fos. Although Fra-1 was up-regulated 
on protein level, and c-Jun:Fra-1 complexes display higher binding activities to DNA than c-
Jun:c-Fos complexes (Ryseck and Bravo, 1991), c-Fos was not excluded from the complex 
and replaced by Fra-1 (Fig. 4-5C). The high amounts of c-Fos compared to the still low 
amounts of Fra-1 most likely inhibit a shift of AP-1 composition. 
In HeLa cells, the increase of c-Jun and the decrease of c-Fos proteins led to a shift 
from c-Jun:c-Fos heterodimers to c-Jun homodimers, as shown by “super shift”- analysis (Fig. 
4-5D). Binding of AP-1 to its consensus sequence remained unchanged, as shown by EMSA-
analysis (Fig. 4-5A), because the alterations of c-Jun and c-Fos led rather to a different com-
position, but not to different amounts of AP-1. 
 
 
5.2.2. Modulation of AP-1 activity as shown by exogenous reporter assays 
The results of the EMSA-analysis were further validated with an AP-1 responsive re-
porter gene. In this study, an exogenous reporter system was used to monitor the transcrip-
tional activity of AP-1 instead of an endogenous AP-1 target gene. Due to the experimental 
approach with the global impact on miRNAs, many unknown, direct and indirect, effects might 
influence endogenous target genes making them inapplicable for the analysis of a single tran-
scription factor. 
The reporter system pAP-1 showed that, upon depletion of Drosha and Dicer, the in-
creased levels of AP-1 in 444 cells led to an enhanced transcriptional activity (Fig. 4-6). This 
is most likely mediated by c-Jun homodimers, since c-Jun:Fra-1 dimers act as transcriptional 
attenuators (Suzuki et al., 1991; Zhang et al., 2004) or only as moderate transcriptional activa-
tors that are preferentially involved in initiation and maintenance of, for example, HPV-16/-18 
transcription (Cripe et al., 1990; Butz and Hoppe-Seyler, 1993). The different activities of c-
Jun:Fra-1 complexes might rely on post-translational modifications, e.g. phosphorylation. Ad-
ditionally, transcription of the luciferase reporter gene might also be driven by AP-1 complexes 
involving JunB that was up-regulated in 444 cells (Fig. 4-2A, lane 5). 
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As expected, CGL3 cells did not show any effect on transcriptional activity (Fig. 4-6). 
In HeLa cells, the loss of c-Jun:c-Fos dimers that act as strong transcriptional activators 
(Suzuki et al., 1991; Zhang et al., 2004) is presumably compensated with the positive regula-
tory effect of c-Jun homodimers. Thus, the transcriptional activity of AP-1 in HeLa cells re-
mained unaltered (Fig. 4-6). 
In conclusion, it was shown that miRNAs can selectively modulate AP-1 formation and 
activity, which potentially alters the transcriptional rate of endogenous target genes. 
 
 
5.3. miRNAs directly regulate c-Jun, Fra-1 and Net 
Reporter assays with fusion transcripts of Renillla luciferase and the 3’UTRs of c-Jun, 
Fra-1 and Net indicated direct miRNA interactions for all three genes (Fig. 4-6). Regarding c-
Jun that previously showed similar increases of mRNA (Fig. 4-2, lane 4) and protein (Fig. 4-3) 
for both knockdowns, Renilla activity upon Drosha depletion was consistently low for unknown 
reasons. The Net construct also did not respond to the knock-down of Drosha, which, how-
ever, was in agreement with the qRT-PCR analysis and was already discussed in chapter 5.1. 
Single segments of c-Jun and Fra-1 were even more sensitive to the miRNA effect 
than the full-length 3’UTRs in the luciferase assays by showing more pronounced effects (Fig. 
4-8). The shorter segments were presumably more accessible to miRNAs, possibly due to re-
duced formation of secondary structures (Doench and Sharp, 2004; Robins et al., 2005). 
 
Taken together, these results indicate that c-Jun and Fra-1 are regulated via multiple 
miRNA binding sites throughout their 3’UTRs. The finding that a target gene is repressed by 
one or several miRNAs via different binding sites is not unusual. For example, human HMGA2 
(high mobility group AT-hook 2) is regulated via six let-7 binding sites in its 3’UTR (Lee and 
Dutta, 2007). Moreover, miR-93, -98 and -197 synergistically target the tumor suppressor 
FUS1, also termed “TUSC2” (tumor suppressor candidate 2) (Du et al., 2009). It has been 
proposed that regulation via multiple binding sites allows a more efficient inhibition (Doench et 
al., 2003). 
c-Jun and Fra-1 are transcription factors involved in a broad range of physiological and 
pathological processes modulating different cellular responses through selective gene tran-
scription. AP-1 activating stimuli encompass cytokines, growth factors, stress signals and in-
fections, which can lead to cellular proliferation, differentiation, apoptosis or neoplastic trans-
formation (Angel and Karin, 1991; Eferl and Wagner, 2003; Hess et al., 2004). miRNA-
mediated regulation of such complex pathways can be easier coordinated, when different pro-
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teins of the same pathway are targeted simultaneously. For example, the miR-16 family mem-
bers miR-15a, miR-16 and miR-103 regulate directly and indirectly genes that cooperatively 
control cell cycle progression (Linsley et al., 2007). Secondly, miR-34a induces G1 cell cycle 
arrest by targeting CCND1 (cyclin D1) and CDK6 (cyclin-dependent kinase 6) (Sun et al., 
2008) and thereby preventing phosphorylation of pRb (protein retinoblastoma 1), which, in the 
hypophosphorylated state, inhibits the E2F family of cell cycle transcription factors. Addition-
ally, it seems that miR-34a also directly targets E2F-1 and -3 (Tazawa et al., 2007). In conclu-
sion, this illustrates that proteins participating in the same regulatory pathway can be simulta-
neously inhibited by miRNAs in order to achieve a functional effect. 
Consequently, a protein that is involved in various miRNA-regulated pathways can be 
targeted by several miRNAs in response to different stimuli. This might be the case for c-Jun 
and Fra-1, for which many regulatory miRNAs are predicted. 
 
 
5.4. Bioinformatics and expression analysis 
5.4.1. Prediction analysis 
Prediction software tools, such as miRBase, TargetScan, PicTar and DIANA microT, 
are useful tools to decipher miRNA target genes (Bartel, 2009). The combined application of 
these programs led to a list of putative miRNAs that were sorted according to the frequency of 
citations and to the number of predicted binding sites. This list, however, is biased by several 
factors. 
 The search engines and the underlying algorithms do not work with the same set of 
annotated miRNAs. Consequently, a true prediction might not receive a high score, 
since it is not considered by all search engines. 
 The algorithms use the criterion of seed pairing between miRNA and mRNA as one 
important parameter, although stringent seed pairing is not a completely reliable pre-
dictor for miRNA binding (Didiano and Hobert, 2006). 
 Seed pairing is not uniformly defined, and shorter seed pairing is partially allowed 
when it is compensated by additional 3’ end pairing of the miRNA, e.g. DIANA microT 
(Maragkakis et al., 2009). 
 Sequence conservation among different species is an important criterion that, how-
ever, does not exclude functional miRNA:mRNA interactions that only exist in hu-
mans. 
 Unknown, functional miRNAs are, of course, not considered by the analysis. 
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Though the bioinformatics approach faces some difficulties, it is still a valid and widely 
used strategy (Gabriely et al., 2008; Tokumaru et al., 2008; Du et al., 2009). 
 
 
5.4.2. miRNA expression analysis in 444 and CGL3 cells 
Besides applying prediction engines in order to find eligible candidate miRNAs, the 
analysis of the miRNome of 444 and CGL3 cells revealed the expression status of 470 anno-
tated miRNAs. This data was used to decipher the high-ranking candidate miR-495 for c-Jun 
regulation. Additionally, the data provides the basis for the question, why c-Fos is not modu-
lated by two miRNAs as it was previously published (Lee et al., 2006; Li et al., 2009). 
It was reported that c-
Fos was repressed in the 
brain of mice by mmu-miR-
7b (Lee et al., 2006) and in 
human liver cells by hsa-
miR-101 (Li et al., 2009). 
Since miRNA-mediated 
regulation is highly con-
served, both miRNAs, when 
expressed, were expected to 
repress c-Fos also in cervi-
cal carcinoma derived cell 
lines. However, the data, 
presented in the present 
study, did not show a direct 
regulation of c-Fos neither in 
444, CGL3 nor HeLa cells. 
Despite the fact that many 
miRNAs are conserved 
across different species, mmu-miR-7b does not have a human homolog. In humans, however, 
there is a closely related variant, named hsa-miR-7, which differs only by one nucleotide 
(UA) (Fig. 5-1). As shown by the miRNA expression profiling, hsa-miR-7 is strongly ex-
pressed in 444 and CGL3 cells (Tbl. 4-4). The detailed analysis of both predicted binding sites 
in the 3’UTRs of human and murine c-Fos (Lee et al., 2006) reveals that the first miRNA bind-
ing site contains one mutation between homo sapiens and mus musculus, whereas the sec-
ond binding site is identical (Fig. 5-1). The alignment of both target sites with the respective 
 
Fig. 5-1: Sequence alignment of miR-7/-7b with its predicted 
target sites within human and murine c-Fos 3’UTR 
Alignment of the two sections of human and murine c-Fos 3’UTRs with 
mmu-miR-7b and hsa-miR-7. In bold: predicted miRNA target site in the 
mRNA; in red: sequence variations between mmu-miR-7b and hsa-miR-
7; highlighted in yellow: putative base-pairing between mRNA and 
miRNA; highlighted in black: lost base-pairing. See text for further de-
tails. 
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miRNAs shows that the (UA) conversion abolishes one base-pairing between hsa-miR-7 
and human c-Fos mRNA in the first miRNA binding site. Additionally, the mutation (GA) of 
human c-Fos mRNA leads to a second loss of base-pairing compared to murine c-Fos 3’UTR 
and mmu-miR-7b. The alignment of the second binding site with the respective miRNAs dis-
plays no difference in the number of hybridized bases, suggesting that the hsa-miR-7-
mediated regulation of human c-Fos is presumably lost due to the impairment of one of two 
binding sites. 
The other miRNA that is reported to regulate c-Fos in human liver cells is miR-101 (Li 
et al., 2009). miR-101 is highly expressed in 444 and CGL3 cells (Tbl. 4-4) and no mutation 
was detected upon sequencing of c-Fos 3’UTR in CGL3 cells compared to the annotated se-
quence. This suggests that other factors inhibit miR-101-mediated degradation of c-Fos 
mRNA in cervical carcinoma derived cell lines, as it is discussed in chapter 5.6. Alternatively, 
the possibility remains that miR-101 was not affected by the transient knock-downs of Drosha 
and Dicer, as discussed in chapter 5.1. In order to exclude miR-101 regulation of c-Fos in this 
cell system, miR-101 would need to be selectively inhibited in further experiments. 
 
 
5.5. miR-495 as a potential regulator of c-Jun 
Co-transfection of miR-495 with Renilla-c-Jun 3’UTR full-length and Renilla-c-Jun 
3’UTR segment 2 reporter plasmids in 444 cells did not significantly reduce Renilla activity 
(Fig. 4-11) indicating that miR-495 does not regulate c-Jun. However, a regulatory effect of 
miR-495 can not be completely ruled out because it is possible that miR-495 contributes to a 
cooperative regulation of c-Jun with other miRNAs. Previous studies have already shown the 
phenomenon of cooperative regulations by miRNAs (Tay et al., 2008; Du et al., 2009). Over-
expression of one regulatory miRNA might then not be sufficient to repress the target mRNA. 
If the amount of the mature miRNA is the key parameter, a possible regulatory effect 
could be elucidated by increasing the miRNA concentration. This would augment the 
miRNA:transcript ratio and potentially reveal an interaction, as long as cooperating partners 
are not titrated out. 
If the amount of transfected miR-495 does not play the decisive role in 444 cells, pos-
sibly because miR-495 steady-state levels are already high enough to repress all target 
mRNAs, alternative approaches must be taken. Firstly, overexpression in CGL3 cells, which 
are devoid of miR-495, might reveal the putative interaction. Secondly, endogenous miR-495 
in 444 cells could be inhibited by antagomirs (Krutzfeldt et al., 2005) or a “miRNA-sponge” 
(Ebert et al., 2007) in order to decipher a potential repressive effect. 
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In conclusion, although miR-495 is likely to regulate c-Jun, such an interaction was not 
proven in the present study. 
 
 
5.6. Possible mechanisms that abolish miRNA-mediated regulation of c-Jun in CGL3 
cells 
It was shown that c-Jun is regulated by miRNA(s) in 444 and HeLa cells, although the 
specific miRNA(s) could not be identified. However, it was demonstrated that in CGL3 cells 
this type of regulation is lost, since c-Jun levels did not change upon depletion of Drosha and 
Dicer. Other reports provide examples of silenced miRNAs that could possibly explain why c-
Jun is not regulated by miRNAs in CGL3 cells. 
Firstly, miRNA genes can be disrupted, since they are often located in / near FRAs 
(fragile sites) and genomic regions that are prone to severe alterations (Calin et al., 2004b), 
such as deletions or translocations. Alternatively, similar to protein-coding genes, the pro-
moter activity of miRNA genes is regulated by many Pol II-associated transcription factors 
(Corcoran et al., 2009; Wang et al., 2009), including tumor-suppressive and oncogenic tran-
scription factors, and can be silenced by transcriptional repressors in trans. Secondly, RNA-
binding proteins can facilitate (Guil and Caceres, 2007) or inhibit (Newman et al., 2008; Hagan 
et al., 2009) processing of miRNA precursors leading to an enhanced or reduced activity of 
mature miRNAs, respectively. Thirdly, sequence variations, such as editing or point mutations, 
can result in impaired miRNA processing (Yang et al., 2006; Kawahara et al., 2007a) or target 
sequence specificity (Kawahara et al., 2007b). 
In conclusion, without knowing the specific miRNA that regulates c-Jun in 444 cells, it 
can only be speculated about the mechanism how this regulation is abolished in CGL3 cells. 
Numerous possibilities were described, of which only the most likely are mentioned here. 
 
 
5.7. Conclusion 
The present study describes for the first time that the AP-1 family members c-Jun, Fra-
1 and c-Fos, are selectively regulated by miRNAs in HPV18-positive cervical carcinoma cell 
lines. Thereby, all three AP-1 members were found to be differently regulated by miRNAs in 
the three analyzed cell lines, which presumably attributes to the different lineages. Most im-
portantly, miRNA-mediated regulation of c-Jun is abrogated in tumorigenic hybrid cells com-
pared to non-tumorigenic progenitor cells. This loss of miRNA-mediated repression inhibits c-
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Jun degradation and may serve as an evasive strategy for the tumorigenic hybrids in order to 
preserve the low basal amounts of c-Jun. 
 
 
Fig. 5-2: Model of the different miRNA-mediated regulation of c-Jun in 444 and CGL3 cells 
c-Jun is repressed by unknown miRNAs in 444, but not in CGL3 cells. miRNA-mediated regulation in CGL3 cells 
is abolished potentially through alterations at (A) the genomic levels, (B) the maturation step, (C) the steady-state 
level, or (D) the target repression step, as discussed in chapter 5.6. For further details see text. 
c-Jun mRNA levels are lower in CGL3 than in 444 cells (as indicated by the size of the boxes), possibly due to 
different transcriptional rates and / or different turn-over of the mRNA. 
 
Furthermore, a miRNA expression array illustrates different miRNA expression profiles 
for the non-malignant and malignant hybrid cells. In combination with bioinformatics prediction 
analysis, these data reveal putative regulatory miRNAs for c-Jun and Fra-1, although no regu-
latory miRNA could be identified in the present study. 
Besides influencing protein levels, it is also shown for the first time that miRNAs modu-
late AP-1 composition and transcriptional activity, thereby providing further examples of 
miRNA-regulated transcription factors that in turn differentially regulate target genes. By 
modulating only one miRNA-responsive AP-1 member, cells might be able to regulate via 
miRNAs various target genes of one specific AP-1 dimer composition. Since AP-1 is a master 
regulator of many cellular processes like proliferation and differentiation, this study underlines 
the complexity of many networks involving the transcription factor AP-1, and it describes how 
miRNAs can contribute to this regulation in cervical carcinoma cells and maybe also in other 
tissues. 
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7.1. Abbreviations 
A Ampere 
AP-1 Activating protein 1 
ATF-2 Activating transcription factor 2 
ATP Adenosin 5’-triphosphate 
bp Basepair 
BSA Bovine serum albumin 
cDNA Complementary DNA (from mRNA) 
c-Fos Cellular FBJ murine osteosarcoma viral oncogene homolog 
c-Jun Jun oncogene 
°C Degree Celsius 
Ci Curie 
CIA Chloroform-Isoamyl alcohol 49:1 
CIAP Calf Intestine Alkaline Phosphatase 
cpm Counts per minute 
DEPC Diethyl pyrocarbonat 
DNA Deoxyribonucleic acid 
dNTP 2’ Deoxynucleosite-5’-triphosphate 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxide 
ds Double-stranded 
DTT Dithiothreitol 
E-64 N-N-(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucyl-agmatine 
ECL-Reagent Enhanced Chemiluminescence Reagent 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethylene glycol-bis[β-aminoethylether]-N,N,N’,N’-tetraacetic acid 
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EMSA Electrophoresis mobility shift assay 
F Forward 
FBS FCS Fetal Calf Bovine Serum 
FosB FBJ murine osteosarcoma viral oncogene homolog B 
Fra-1 FOS-like antigen 1 
Fra-2 FOS-like antigen 2 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
h Hour 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP Horseradish peroxidase 
IgG Immunoglubuline G 
JDP2 Jun dimerization protein 2 
JunB Jun B proto-oncogene 
JunD Jun D proto-oncogene 
kbp Kilobasepair 
kDa Kilodalton 
LB-Medium Luria-Bertani medium 
M Molar 
min Minute 
ml Milliliter 
MOPS 3-[N-Morpholino]-propanesulfonic acid 
mRNA Messenger RNA 
miRNA MicroRNA 
Net New ETS transcription factor (also known as ELK3) 
Oct-1 Octamer-binding transcription factor 1 
OD Optical density 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
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PCR Polymerase chain reaction 
pDNA Plasmid DNA 
Pefabloc SC 4-(2-Aminoethyl)-benzensulfonylfluoride 
Pen Penicillin 
PMSF Phenylmethanesulphonylfluoride 
pre-miRNA Precursor miRNA 
pri-miRNA Primary miRNA 
PVDF Polyvinylidene fluoride 
qRT-PCR quantitative reverse transcription-PCR 
R Reverse 
RNA Ribonucleic acid 
RNase Ribonuclase 
rpm Revolutions per minute 
RT Reverse transcription 
sd Single-stranded 
s.d. Standard deviation 
sec Second 
SDS Sodium dodecyl sulphate 
SDS-PAGE Denaturing polyacrylamid gel electrophoresis 
S.O.C. SOB medium (Super Optimal Growth) with 20mM Glucose 
SSC Standard saline-citrate 
Strep Streptomycin 
TA Annealing temperature 
TAE TRIS-acetate-EDTA 
TBS TRIS-buffered saline 
TBST TRIS-buffered saline with Tween 
TE TRIS-EDTA 
TEMED N,N,N',N'-Tetramethylethylenediamine 
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TRIS Tris(hydroxymethyl)-aminomethan 
U Unit (enzymativ activity) 
V Volt 
v/v Volume precentage 
w/v Weight percentage 
 
 
7.2. Alignment of putative regulatory miRNAs with c-Jun and Fra-1 3’UTRs 
7.2.1. Alignment of predicted miRNAs with c-Jun 3’UTR 
Nt Search 
engine 
Pred. 
miRNA 
 
 
2040 
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2134 
 
 
 
2194 
 
2254 
 
 
 
 
2314 
 
 
 
 
 
2374 
 
2434 
 
2494 
 
 
 
 
2554 
 
 
 
 
 
 
 
 
2614 
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1,3 
3,4 
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1,3,4 
 
 
 
 
 
 
3,4 
3,4 
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3 
3 
1,3 
1,3 
2 
2,3 
2,3,4 
 
 
 
 
 
891b 
 
 
637 
517c 
 
 
 
 
 
 
 
 
429 
200b 
200c 
 
 
92a 
92b 
32 
139-5p 
 
 
 
 
 
 
524-5p 
520d-5p 
340 
 
 
524-5p 
520d-5p 
200a 
141 
340 
612 
495 
 
 
Linker             stop codon 
AGGGCGATCGCCTCGAGACATTTTGAAGAGAGACCGTCGGGGGCTGAGGGGCAACGAAGA 
 
                        AGTTACTGAGTCCATTCAACGT 
AAAAAAATAACACAGAGAGACAGACTTGAGAACTTGACAAGTTGCGACGGAGAGAAAAAA 
 
                                             UGCGUCUCGGGCUUU 
                                                        UGUG 
GAAGTGTCCGAGAACTAAAGCCAAGGGTATCCAAGTTGGACTGGGTTGCGTCCTGACGGC 
 
CGGGGGUCA 
AGAUUUUCCUACGUGCUA 
GCCCCCAGTGTGCACGAGTGGGAAGGACTTGGCGCGCCCTCCCTTGGCGTGGAGCCAGGG 
 
AGCGGCCGCCTGCGGGCTGCCCCGCTTTGCGGACGGGCTGTCCCCGCGCGAACGGAACGT 
 
                                          UGCCAAAAUGGUCUGUCA 
                                          aguAGUAAUGGUCCGUCA 
                                          GGUAGUAAUGGGCCGUCA 
TGGACTTTTCGTTAACATTGACCAAGAACTGCATGGACCTAACATTCGATCTCATTCAGT 
 
                  GUCCGGCCCUGUUCACGUUAU 
UAAU             CCUCCGGCCCUGCUCACGUUAU 
UAAU              CGUUGAAUCAUUACACGUUAU 
UAAU                            UCUGUGCACGUGACAUCU 
ATTAAAGGGGGGAGGGGGAGGGGGTTACAAACTGCAATAGAGACTGTAGATTGCTTCTGT 
 
AGTACTCCTTAAGAACACAAAGCGGGGGGAGGGTTGGGGAGGGGCGGCAGGAGGGAGGTT 
 
TGTGAGAGCGAGGCTGAGCCTACAGATGAACTCTTTCTGGCCTGCCTTCGTTAACTGTGT 
 
                                                 CUCUUUCACGA 
                                                   CUUUCCCGA 
                                                 TTAGTCAGAGT 
ATGTACATATATATATTTTTTAATTTGATGAAAGCTGATTACTGTCAATAAACAGCTTCA 
 
AGGGAAACAUC                           CUCUUUCACGAAGGGAAACAUC 
AGGGAAACAUC                             CUUUCCCGAAGGGAAACAUC 
                               UGUAGCAAUGGUCUGUCACAAU        
                               GGUAGAAAUGGUCUGUCACAAU        
AACGAAATATT                                                  
                        uuccuCGAGUCUUCGGGACGGGUCG            
       uucUUCACGUGGUACAAACAAA                                
TGCCTTTGTAAGTTATTTCTTGTTTGTTTGTTTGGGTATCCTGCCCAGTGTTGTTTGTAA 
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3274 
1 
3 
3 
2,3 
 
 
3 
3 
 
 
1,3,4 
 
 
 
 
 
 
3 
 
 
 
3 
3 
 
 
2,3 
 
 
3 
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3,4 
32 
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520d-5p 
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501-5p 
362-5p 
 
 
139-5p 
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501-5p 
362-5p 
 
 
642 
 
 
522 
340 
 
 
 
 
 
 
 
340 
 
 
                   CGUUGAAUCAUUACACGUUAU 
                CUCUUUCACGAAGGGAAACAUC   
                  CUUUCCCGAAGGGAAACAUC   
             UGUGAGAUUUCCCUUGGUAAAA      
ATAAGAGATTTGGAGCACTCTGAGTTTACCATTTGTAATAAAGTATATAATTTTTTTATG 
 
       AGAGUGGGUCCCUGUUUCCUAA 
     UGAGUGUGGAUCCAAGGUUCCUAA 
TTTTGTTTCTGAAAATTCCAGAAAGGATATTTAAGAAAATACAATAAACTATTGGAAAGT 
 
                UCUGUGCACGUGACAUCU 
ACTCCCCTAACCTCTTTTCTGCATCATCTGTAGATACTAGCTATCTAGGTGGAGTTGAAA 
 
 
 
GAGTTAAGAATGTCGATTAAAATCACTCTCAGTGCTTCTTACTATTAAGCAGTAAAAACT 
 
                                                      UGCGUC 
GTTCTCTATTAGACTTTAGAAATAAATGTACCTGATGTACCTGATGCTATGGTCAGGTTA 
 
UCGGGCUUUCGGGGGUCA 
                          AGAGUGGGUCCCUGUUUCCUAA 
                        UGAGUGUGGAUCCAAGGUUCCUAA 
TACTCCTCCTCCCCCAGCTATCTATATGGAATTGCTTACCAAAGGATAGTGCGATGTTTC 
 
                GUUCUGUGUAAACCUCUCCCUG 
AGGAGGCTGGAGGAAGGGGGGTTGCAGTGGAGAGGGACAGCCCACTGAGAAGTCAAACAT 
 
                      UUGUGAGAUUUCCCUUGGUAAAA 
                          TTAGTCAGAGTAACGAAATATT 
TTCAAAGTTTGGATTGTATCAAGTGGCATGTGCTGTGACCATTTATAATGTTAGTAGAAA 
 
TTTTACAATAGGTGCTTATTCTCAAAGCAGGAATTGGTGGCAGATTTTACAAAAGATGTA 
 
                                                   TTAGTCAGA 
TCCTTCCAATTTGGAATCTTCTCTTTGACAATTCCTAGATAAAAAGATGGCCTTTGCTTA 
 
GTAACGAAATATT                                     Linker 
TGAATATTTATAACAGCATTCTTGTCACAATAAATGTATTCAAATACCAAGTTTAAACGC 
 
GGCCGCACG 
 
miRNAs that are predicted to align with c-Jun 3’UTR are displayed. Nucleotides (Nt) indicate the position within the 
3’UTR starting counting with the first nucleotide after the stop codon TGA. miRNAs are predicted by (1) PicTar, (2) 
miRBase, (3) TargetScan, (4) DIANA microT. Nucleotides of miRNAs that presumably base-pair with the 3’UTR are 
highlighted in yellow. Nucleotides of the 3’UTR that belong to anterior and posterior segments are highlighted in tur-
quoise. Nucleotides of the 3’UTR that are underlined are part of the Linker for cloning purposes. 
miR-495 is predicted to have two overlapping binding sites, of which only one is indicated in the figure. 
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7.2.2. Alignment of predicted miRNAs with Fra-1 3’UTR 
Nt Search 
engine 
Pred. 
miRNA 
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571 
299-3p 
138 
138 
 
 
338-5p 
149 
138 
 
 
130a 
19a 
19b 
593 
 
 
130a 
593 
593 
149 
22 
 
 
449b 
34c-5p 
525-5p 
520a-
5p 
449a 
34a 
 
 
513a-
5p 
571 
296-3p 
 
 
449b 
571 
449a 
34c-5p 
34a 
138 
138 
138 
 
 
 
566 
 
 
646 
15b 
15a 
16 
195 
22 
 
 
 
Linker   stop codon 
TCGAGTCGCTTTGTGAGGCGCCTGAGCCCTACTCCCTGCAGATGCCACCCTAGCCAATGT 
 
                                    GAGUGAGUCUACCGGUUGAGU    
                            UUCGCCAAAUGGUAGGGUGUAU           
           CUAAGUGUUGUGGUCGA                                
                                            CUAAGUGUUGUGGUCG 
CTCCTCCCCTTCCCCCACCGGTCCAGCTGGCCTGGACAGTATCCCACATCCAACTCCAGC 
 
                   GUGAGUCGUGGUCCUAUAACAA 
                                     CCUCACUUCUGUGCCUCGGUCU  
A                                          CUAAGUGUUGUGGUCGA 
AACTTCTTCTCCATCCCTCTAATGAGACTGACCATATTGTGCTTCACAGTAGAGCCAGCT 
 
                                        UACGGGAAAAUUGUAACGUG 
                                      AGUCAAAACGUAUCUAAACGUGU 
                                      AGUCAAAACGUACCUAAACGUGU 
                                                      UCUUUG 
TGGGGCCACCAAAGCTGCCCACTGTTTCTCTTGAGCTGGCCTCTCTAGCACAATTTGCAC 
 
AC 
                                        UCUUUGGGGUCGUCUCUGU 
GGGUCGUCUCUGU                                                 
              CCUCACUUCUGUGCCUCGGUCU                          
                              UGUCAAGAAGUUGACCGUCGAA         
TAAATCAGAGACAAAATATTTCCCATTTGTGCCAGAGGAATCCTGGCAGCCCAGAGACTT 
 
                              CGGUCGAUUGUUAUGUGACGGA 
                             UUGUUGGUCGAUUCUGUGACGGU 
     UCUUUCACGUAGGGAGACCUC                                
     UCUUUCAUGAAGGGAGACCUC                                  
                              UGGUCGAUUGUUAUGUGACGGU 
                              UGUUGGUCGAUUCUGUGACGGU   
TGTAGATCCTTAGAGGTCCTCTGGAGCCCTAACCCCTTCCAGATCACTGCCACACTCTCC 
 
 UACUGUGGAGGGACACUU 
                                                         GAG 
          CCUCUCGGAGGUGGGUUGGGAG 
ATCACCCTCTTCCTGTGATCCACCCAACCCTATCTCCTGACAGAAGGTGCCACTTTACCC 
 
           CGGUCGAUUGUUAUGUGACGGA 
UGAGUCUACCGGUUGAGU                                    
           UGGUCGAUUGUUAUGUGACGGU                          
          CGUUAGUCGAUUGAUGUGACGGA                      
           UGUUGGUCGAUUCUGUGACGGU                       
                      CUAAGUGUUGUGGUCGA                       
                   CUAAGUGUUGUGGUCGA        
       CUAAGUGUUGUGGUCGA                                 
ACCTAGAACACTAACTCACCAGCCCCACTGCCAGCAGCAGCAGGTGATTGGACCAGGCCA 
 
 
                       CAACCCUAGUGUCCGCGGG 
TTCTGCCGCCCCCTCCTGAACCGCACAGCTCAGGAGGCGCCCTTGGCTTCTGTGATGAGC 
 
                                                       CGGAG 
                                                    ACAUUUGG 
                                                    GUGUUUGG 
                                                    GCGGUUAU 
                                                     CGGUUAU 
                                                 UGUCAAGAAGU 
TGATCTGCGGATCTCAGCTTTGAGAAGCCTTCAGCTCCAGGGAATCCAAGCCTCCACAGC 
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1588 
 
1648 
 
2,3 
2,3 
1,3 
1,3 
1,3 
1,3 
1,3 
 
 
 
 
 
 
646 
568 
15b 
15a 
16 
195 
22 
 
 
 
 
UCUCCGUCGACGAA 
                          CACACAUAUGUAAAUAUGUA 
UACUACACGACGAU                                               
UAAUACACGACGAU                                                
AAAUGCACGACGAU                                               
AAAGACACGACGAU                                                
UGACCGUCGAA                                                  
GAGGGCAGCTGCTATTTATTTTCCTAAAGAGAGTATTTTTATACAAACCTACCAAAATGG 
                    Linker 
AATAAAAGGCTTGAAGCTGTGGTTTAAACGC 
miRNAs that are predicted to align with c-Jun 3’UTR are displayed. Nucleotides (Nt) indicate the position within the 
3’UTR starting counting with the first nucleotide after the stop codon TGA. miRNAs are predicted by (1) PicTar, (2) 
miRBase, (3) TargetScan, (4) DIANA microT. Nucleotides of miRNAs that presumably base-pair with the 3’UTR are 
highlighted in yellow. Nucleotides of the 3’UTR that belong to anterior and posterior segments are highlighted in tur-
quoise. Nucleotides of the 3’UTR that are underlined are part of the Linker for cloning purposes. 
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